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ABSTRACT 
INTRODUCTION:  Since 2006, the Advisory Committee for Immunization Practices (ACIP) 
has recommended routine vaccination of adolescent girls at ages 11 or 12 years with 3 doses of 
human papillomavirus (HPV) vaccine to prevent cervical cancer.  Cervical cancer disparities 
exist for several populations in the United States.  The topic is scantly documented in scholarly 
literature with modest knowledge of the uptake of the HPV vaccine in the Delta region. 
AIM: To examine the HPV vaccination coverage estimates in the counties and parishes that 
comprise the Delta Regional Authority (DRA) and compare with other non-DRA counties or 
parishes and the rest of US.  This will provide vaccination coverage estimates for adolescent 
females in the DRA designated Delta region that will provide public health professionals with data 
for policy and programmatic decision-making.  
METHODS: We combined data from multiple survey years (2008-2012) from the National 
Immunization Survey-Teen (NIS-Teen). We conducted bivariate analyses to describe the 
distribution across selected socio-demographic characteristics and multivariable logistic 
regression models to produce adjusted prevalence ratios.  
RESULTS:  Teens in the DRA had lower HPV vaccine initiation and completion rates 
compared to Non- DRA counties or parishes and the Rest of the US.  The 3-dose HPV 
vaccination series completion rate among those who had initiated HPV vaccination and had 24 
weeks between their first dose and the NIS interview date was 60.9% (95% CI: 55.8 – 65.8) 
among adolescent females in the DRA compared to 66.9 (95% CI: 63.7-70.0) of adolescent 
females in the Non-DRA counties and 67.6% (95% CI: 66.2-69.0) in the rest of the US. 
CONCLUSION: The low HPV vaccination coverage among adolescents in the DRA showed 
that it is important to implement additional strategies to increase HPV vaccination coverage that 
 xii 
 
will prevent cancers associated with HPV in the DELTA Region.  Stronger provider 
recommendations and awareness are important for increasing HPV vaccine uptake.  
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CHAPTER I 
INTRODUCTION 
1.1 Background 
Since 2006, the Advisory Committee for Immunization Practices (ACIP) has 
recommended routine vaccination of adolescent girls at ages 11 or 12 years with 3 doses of 
human papillomavirus (HPV) vaccine to prevent cervical cancer (CDC, 2007, 2013).  
Nationwide vaccination coverage with ≥1 dose of HPV vaccine increased from 25.1% in 2007 to 
53.0% in 2011; however, coverage in 2012 (53.8%) was similar to 2011 estimates.  
Cervical cancer disparities exist for several populations in the U.S., including females 
from the Delta region as designated by the Delta Regional Authority (DRA).  The Delta region, 
made up of 252 counties and parishes in eight states (Alabama, Arkansas, Illinois, Kentucky, 
Louisiana, Mississippi, Missouri, and Tennessee), is one of the most historic, culturally saturated 
geographic settings of the country.  Yet, daily life remains a struggle for many; compared with 
national rates, premature deaths in the Delta region from cancer are 12% higher.  The DRA 
strives to create jobs, build communities, and improve the lives of the nearly 10 million people in 
the Delta region.  The DRA believes that health is an economic mechanism that has the capacity 
to drive future economic growth (DRA, 2013).  HPV vaccination offers an impetus for reducing 
cancer-related disparities. 
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1.2 Purpose of Study  
There is inadequate documentation and limited evidence-based knowledge of the uptake 
of the HPV vaccine in the Delta region.  This thesis aims to provide vaccination coverage 
estimates for adolescent females in the DRA designated Delta region that will provide public 
health professionals with data for policy and programmatic decision-making.  
 
1.3 Research Questions 
 Three research questions were addressed: 
1. What are the HPV vaccination coverage estimates from counties and parishes that 
comprise the Delta Regional Authority (DRA)? 
2. Are there differences in HPV vaccination coverage estimates between the DRA 
compared to other counties or parishes in the Delta states that are not part of the DRA? 
3. Are there differences in HPV vaccination coverage estimates between the DRA 
compared to other Non-Delta states (Rest of U.S.)? 
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CHAPTER II 
REVIEW OF THE LITERATURE 
2.1 The Delta States   
The Delta region (Delta) is located in the central and southern parts of the United States.  
The Delta Regional Authority (Figure 1) is made up of 252 counties and parishes in eight states: 
Alabama, Arkansas, Illinois, Kentucky, Louisiana, Mississippi, Missouri and Tennessee (DRA, 
2013).  The Delta has one of the most fertile soils in the world, with established irrigation 
technology to complement its untapped agricultural resources. Additionally, the Delta boasts of 
rich cultural history that sets a respectable standard with its peers.  During the 1800s, cotton was 
a main cash crop throughout the Delta (especially Arkansas and Mississippi) and African-
American slaves worked on the farms.  Before the Civil War, the largest percentage of slaves 
lived in the Delta and made up the majority of the Delta population.  In spite of its rich 
agricultural resources, the Delta region faced unfavorable race relations, severe poverty, and a 
resistance to social change that affected its economic development (Gray 1991, 238).  For 
example, in 2000, about 17.0% of the population of Missouri and 12.5% of the population of 
Louisiana lived below the poverty line. 
The health status of the Delta population is also poor, compared to that of the rest of the 
nation.  For example, compared with national rates, deaths in the Delta region from cancer are 
12% higher. 
The Delta is overseen by the Delta Regional Authority (DRA, 2013).  The DRA was 
established in 2000 by an Act of Congress to work towards economic development and improve 
living standards for residents of the Delta region.  DRA has since made major improvements 
towards job creation, building communities, and the enhancement of the lives of almost ten 
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million people in the Delta region.  The DRA considers health as one of the areas of importance 
for economic growth; they refer to health as an economic engine (DRA, 2013).  
Figure 1 
 
 
2.2 Cervical Cancer in the United States  
 The World Health Organization (WHO) and International Agency for Research on 
Cancer (IARC) estimate that in 2012, about 8.2 million people died from cancer (GLOBOCON 
2012, IARC).  Cancer is the second leading cause of death in the United States.  The American 
Society of Clinical Oncology (ASCO) projects that cancer could be leading cause of death in 
United States by 2030.  Cervical cancer was the primary cause of cancer death among women in 
the United States.  Early screening methods, such as Papanicolaou test (PAP tests) have served 
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as an intervention to find precancerous cells earlier.  This intervention has helped to reduce 
cervical cancer deaths, and they are no longer listed among the three most common cancers 
among females.  
Since 2006, the Advisory Committee for Immunization Practices (ACIP) has 
recommended routine vaccination of adolescent girls at ages 11 or 12 years with 3 doses of 
human papillomavirus (HPV) vaccine to prevent cervical cancer (CDC, 2007, 2013).  Although 
nationwide vaccination coverage with ≥1 dose of HPV vaccine increased from 25.1% in 2007 to 
53.0% in 2011, coverage in 2012 (53.8%) was similar to 2011 rates.   
Even though there has been reduction in cervical cancer in the US, disparities do exist. 
The Centers for Disease Control and Prevention estimates that in 2010, incidence rates of 
cervical cancer were highest among black women, followed by Hispanic, White, American 
Indian/Alaska native and Asians/Pacific Islander women in that order (CDC, 2013).  Cervical 
cancer disparities exist for several populations and geographic areas in the United States.  As of 
2010, most of the southern states in the US exhibited the highest cervical cancer incidence rates 
of between 8.1 – 11.2 per 100,000 (data were not available on cervical cancer rates for Arkansas) 
(CDC, 2014).  Furthermore, disparities exist among females from the Delta states as designated 
by the Delta Regional Authority (DRA) and even possibly among females from the Delta region.   
 
2.3 HPV Vaccination in the United States 
Human Papillomavirus vaccination (HPV) offers a strategy for reducing these disparities.  
Vaccines against the (HPV) help to prevent cervical cancer and other HPV related infections.  
HPV vaccines have played a major role in reducing cervical cancer incidence.  Different 
countries may have different target ages for routine and catch up vaccinations against HPV 
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(Hariri, Markowitz, Dunne, & Unger, 2013).  The 3-dose vaccine series is given over six months. 
Cervarix and Gardasil are HPV vaccines that protect against cervical cancer whereas Gardasil 
also has protective effects against genital warts, vulvar, vaginal and anal cancers.  Gardasil is 
therefore recommended for vaccination among males.  The CDC recommends vaccination 
among girls and boys at ages 11 to 12 years.  Preteen vaccination is an important protection 
measure before they are exposed to the infection.  Teenage girls and women up to age 26 years 
and males up to age 21 years who missed the vaccination in preteen years are recommended to 
have the vaccination.   
The annual report to the nation on status of cancer for 1975 – 2009 showed that about 
32.0% of girls aged 13 to 17 years in US completed the 3-dose regimen for HPV vaccination in 
2010, with lower coverage of about 14.1% among those who had no health insurance.  The 
southern states showed lower HPV vaccination coverage than that of the rest of the US.  
Alabama and Mississippi, for example, recorded rates around 20% (Jemal et al., 2013).  
 
2.4 Determinants of HPV Vaccination in the United States 
Many factors are associated with HPV vaccination uptake in the United Sates.  These 
factors are related to the target group; parents, and providers.  Some strong indicators of HPV 
uptake are provider recommendation, healthcare education and availability of trained health care 
providers.  Most adolescents are willing to be vaccinated based on provider recommendation, 
and parents are more supportive of vaccinating their children when providers recommend HPV 
vaccination. (Ylitalo, Lee, & Mehta, 2013) 
Even though recommendations are important for high vaccine uptake, there are factors 
that make it difficult for health care providers to recommend HPV vaccination to their patients.  
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Bynum, Staras, Malo, Giuliano, Shenkman, and Vadaparampil (2014) found that generally, it 
feels uneasy to discuss sexually transmitted infections with teenagers especially with target 
adolescents.  Other important factors like specialty in the area of sexually transmitted infections, 
infrastructure and an administration that supports recommendation of vaccines against sexually 
transmitted infections are vital in improving HPV vaccination coverage.   
Some healthcare workers in other specialty areas may feel that it is not necessarily their 
focus; however it is important that every health care worker takes each opportunity to educate 
and recommend the uptake of vaccines against sexually transmitted infections especially if the 
vaccines are available (Daley, Vamos, Buhi, Kolar, McDermott, & Hernandez, et al. 2010).  
Healthcare workers should be trained to overcome impediments to recommendation since 
recommendation are major instruments for influencing sexual behaviors and risk education. 
Bynum et al. (2014) also point out certain challenges such as difficulty in ensuring vaccine series 
completion that needs to be addressed.  
For males, health care provider recommendations may be a very important factor that 
may be lacking.  Vadaparamil and colleagues (2013) report from their studies on HPV 
recommendations that some physicians reported that they do not recommend HPV vaccine to 
males.  Many reasons may account for this, including, but not limited to the physicians not being 
aware of new policies, or that they still feel it is the responsibility of other reproductive health 
providers. The Physicians in the study indicated the need for more information on HPV 
vaccination, and knowledge about the safety and efficacy for males (Vadaparampil, Murphy, 
Rodriguez, Malo, & Quinn, 2013). 
Difficulty in completing the vaccine schedule could be due to vaccine availability, 
proximity to health care service areas, time constraints, and inability to pay for vaccines if they 
 8 
 
are not free or in the absence of insurance are many characteristics that can influence change. 
These factors are more patient dependent than provider dependent.   
Access to health care is correlated with race and ethnicity (Gelman, Miller, Schwarz, 
Akers, Jeong & Borrero, 2013).  Gelman, et al. (2013) studied the association between 
race/ethnicity and HPV vaccine initiation and to determine the role of access to health care.  
They assessed 2,168 females aged 15-24 years from nationally representative data from the 
National Survey of Family Growth.  They concluded that the observed lower rates of HPV 
vaccination among African-American females were not explained by difference in access to 
health care.  Further research can explain this relationship as access may affect the interplay 
between vaccine completion and vaccine initiation.  
A study that assessed mothers’ support for school based HPV vaccination found that 
about 67% of mothers who had the intention of vaccination for their daughters were willing to 
allow their daughters to receive the vaccine at school (Kadis, McRee, Gottlieb, Lee, Reiter, & 
Dittus, et al. 2011).  Some mothers (about 40%) expressed their wish to be present during 
vaccination, whereas others (about 64%) expressed the need for their daughters' doctors to keep 
track of their immunizations if they had to take it at school (Kadis, et al. 2011). 
Among patients and parents, there are some misconceptions on vaccination, including 
vaccine efficacy concerns as well as the fear that HPV vaccination will induce promiscuity 
among vaccinated teens, since they feel protected against HPV after vaccination.  Bynum, et al. 
(2014) stress that sexuality communication and family medicine specialty need important 
consideration to help improve HPV vaccination rates. 
Awareness of HPV vaccination plays an important role, and can help with initiation.  It is 
a challenge faced by many populations irrespective of age, race or ethnicity.  Community 
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education on HPV vaccination is a very important tool for increasing vaccine uptake.  Those who 
had the perception that vaccinating against HPV would provide physical and psychological 
benefits expressed intent to vaccinate, whereas those who perceived HPV vaccination as a 
financial burden expressed otherwise (Wheldon, Daley, Buhi, Nyitray, & Giuliano, 2011) 
Guidelines are important for identifying target groups and vaccination schedules as well 
as screening in the prevention of any disease including cervical cancer.  Some practitioners may 
have challenges using guidelines, or may not adhere to treatment and prevention guidelines.  
Three hundred and sixty six obstetrician-gynecologists who were members of the American 
Congress of Obstetricians and Gynecologists (ACOG) were asked about factors and challenges 
that affect HPV vaccination.  Almost all of them (92%) said they offered HPV vaccination to 
their patients.  They said the refusal of parents and patients to take vaccinations were the main 
barriers to HPV vaccination.  The study found that group practitioners were more likely than solo 
practitioners to adhere to HPV vaccination and screening guidelines.  The conclusion was that it 
is important to promote guideline adherence to help with the quality of cervical cancer 
prevention services, since only 27% of practitioners estimated that vaccination was given to the 
most eligible patients (Perkins, Anderson, Gorin, & Schulkin, 2013). 
 
2.5 Disparities in Vaccination 
Although the CDC reports increases in adolescent vaccination coverage from 2006 to 
2011, there are differences in the rate increases based on vaccine type.  The Healthy People 2020 
target for ≥3 HPV vaccine doses among females is 80.0%.  In 2011, coverage with ≥3 HPV 
vaccine doses among females was as low as 30.0%.  States in the south showed significantly 
lower vaccination rates for ≥1 and ≥3 doses of HPV, compared to Northeast and Western states.   
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Coverage with ≥1 dose of HPV ranged from 31.9% (Mississippi) to 76.1% (Rhode Island), and 
coverage for ≥3 doses of HPV, from 15.5% (Arkansas) to 56.8% (Rhode Island).  
Stokley, et al. (2013) state that HPV vaccination coverage for ≥1 dose in 2012 (53.8%) 
was similar to that of 53.0% in 2011 even though there was a slight increase in the coverage.  
The researchers noted that HPV vaccination coverage for ≥1 HPV dose may have been as high as 
92.6% if the HPV vaccine had been administered during health-care visits when other vaccines 
were administered. 
Berry-Cabán & Buenaventura (2009) studied vaccine compliance among 6,154 girls aged 
9 to 17 years who were enrolled in Womack Army Medical Center (WAMC) in November 2006 
using the Composite Health Care System (CHCS) database.  They found that only 25.7% of girls 
aged 9 to 17 years completed the entire 3-dose HPV series; 34.6% received 2 doses, and 39.7% 
received 1 dose (P-value = 0.006).  Even though they do state that factors like use of the Gardasil 
vaccination series and time to complete the series during data collection may have affected the 
results, the finding that about 77% of girls aged 12 to 17 years have not yet been vaccinated is a 
concern for HPV prevention. 
While some socioeconomic and demographic factors indicated disparities in vaccine 
uptake, they may not be associated with vaccination initiation (Kester, Zimet, Fortenberry, Kahn, 
& Shew, 2013).  Research shows that low income and minority adolescents are equally likely to 
start the vaccination compared to their counterparts of high income or majority status, but they 
are less likely than Whites/majority and high income adolescents to complete the 3 dose regimen 
(Jeudin, Liveright, Carmen, & Perkins, 2014).  Kester, et al. (2013) described some racial 
disparities; Blacks and Hispanics are less likely to complete vaccination.  Some reasons for not 
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vaccinating include: concerns about vaccine safety, concerns about the implications/danger to 
adolescent daughter, and provider non-recommendation. 
Fisher, Trotter, Audrey, MacDonald-Wallis, and Hickman (2013) conducted a meta-
analysis using a random-effects model and reviewed disparities in HPV vaccine uptake among 
young women from its inception to March 2012.  Results from analyzing 27 studies with the 
majority of studies conducted in the US showed differences in HPV vaccination initiation by 
ethnicity and healthcare coverage.  They also cited low family income and education as reasons 
for the observed disparities. 
A study assessed HPV vaccination status among 2,205 households with girls aged 9-17 
years in the 2008 National Health Interview Survey.  This study found that disparities in HPV 
vaccine uptake among the age groups: 2.8% (9 to 10 yrs.), 14.7% (11 to 12 yrs.), and 25.4% (13 
to 17 yrs.) had at least 1 dose of HPV vaccine whereas fewer received all 3 doses: 5.5% (11 to 12 
yrs.) and 10.7% (13 to 17 yrs.).  The main reasons stated for non-vaccination were that the 
parents believed the vaccine was not necessary for their daughters (Wong, Berkowitz, Dorell, 
Price, Lee, & Saraiya, 2011). 
  
 12 
 
CHAPTER III  
METHODS AND PROCEDURES  
3.1 Overview  
The National Immunization Survey-Teen (NIS-Teen) is a random-digit-dialing telephone 
survey of parents/guardians of adolescents aged 13-17 years.  NIS-Teen also includes a mailed 
survey to all vaccination providers identified by the parent and for which consent was granted to 
contact for vaccination history (Jain, Singleton, Montgomery, & Skalland, 2009).  The NIS-Teen 
uses a national probability sample of households in the United States, which includes all 50 
states, the District of Columbia, and some select local areas.  It is conducted using the sampling 
frame of telephone numbers selected for the core NIS, which measures vaccination coverage in 
children 19-35 months.  
We analyzed NIS-Teen data from 2008 to 2012.  The data for 2008 to 2010 included 
landline only households while the data for 2011 and 2012 were conducted using landline and 
cellular telephone households (CDC, 2011, 2012).  Provider confirmed vaccination records were 
used to determine all HPV vaccination coverage estimates among females in this study.  
Adolescent females without adequate provider data were excluded from the analysis.  Details of 
the NIS-Teen methodology, including how vaccination data are combined to produce a 
synthesized immunization history and weighting procedures, have previously been published 
(CDC, 2011, 2012).  NIS-Teen was approved by the CDC Institutional Review Board (IRB). 
 
3.2 Study population and setting 
 Our study population was grouped into three geographic categories.  The first category 
and focus of our analysis is the Delta Regional Authority (DRA).  The DRA includes 252 
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counties and parishes in parts of Alabama, Arkansas, Illinois, Kentucky, Louisiana, Mississippi, 
Missouri and Tennessee (DRA, 2013).  The second category includes counties within the Delta 
States that are not considered as part of DRA (Non-DRA counties).  The third category includes 
the remaining U.S. states (rest of USA).  HPV vaccination coverage estimates of adolescent 
females from DRA were compared to estimates in the other two geographic categories.  In this 
study, we include a total of 47, 709 adolescent females aged 13-17 years who participated in the 
NIS-Teen during the period of 2008 to 2012 and had adequate provider data. 
 
3.3 Variables and definitions 
 The outcome for this analysis is HPV vaccination coverage.  We examined four 
dichotomous (yes or no) HPV vaccination coverage measures: (1) initiation: receipt of at least 
one HPV dose; (2) receipt of at least two HPV doses; (3) receipt of at least three HPV doses; and 
(4) completion: receipt of three HPV doses among initiators who had more than 24 weeks 
between the first HPV dose and the interview date.  We examined the following socio-
demographic characteristics of the sample population, Year of interview (2008, 2009, 2010, 
2011, and 2012), Age of Teen in years (13, 14, 15, 16, and 17), Race/Ethnicity (White, non-
Hispanic; Black, non-Hispanic; Hispanic; and Other), Mother’s Education (<High School; High 
School Graduate; >High School, Some College; and College Graduate), Mother’s Marital Status 
(Married; Divorce/Widowed/Separated; and Never Married), Mother’s Age in years (≤34 years; 
35-44 years; and ≥45 years), Teen had a preventive care visit at age 11 or 12  years (Yes; and 
No),  Income to poverty ratio (<133%; 133% - < 322%; 322% - <503%; and >503%), 
Vaccination payment source (Private Only; Medicaid / CHIP; Uninsured; Military; and Other), 
Received provider recommendation for HPV vaccination (Yes; and No), Knowledge about HPV 
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Vaccine (Yes; and No), Heard about HPV vaccine (Yes; and No), Number of Total Providers (1; 
2 – 3; and 4 or more), Facility Type (Private; Public; Hospital; Mixed; and Other), and 
Metropolitan Statistical Areas (MSA) (Urban; Suburban; and Rural Area). Among parents whose 
daughters were unvaccinated and had not received all three doses of HPV, we examined intent to 
vaccinate their daughters in the next year.  These parents were asked, “How likely is it that 
[TEEN] will receive HPV shots in the next 12 months?” Response options included “very 
likely,” “somewhat likely,” “not too likely,” “not likely at all,” and “not sure/don’t know.”  
Parents with responses other than “very likely” were asked, “What is the main reason [TEEN] 
will not receive HPV shots in the next 12 months?” This open-ended survey item allowed 
parents to indicate multiple reasons.  We categorized these responses as (Already Sexually 
Active, Already Up-To-Date, Child Fearful, Child Should Make Decision, College Shot, Costs, 
Don't Believe in Immunizations, Family / Parental Decision, Handicapped / Special Needs / 
Illness, Increased Sexual Activity Concern, Lack of Knowledge, More Info / New Vaccine, No 
Doctor or Doctor's Visit Not Scheduled, No Ob/Gyn, Not A School Requirement, Not 
Appropriate Age, Not Available, Not Recommended, Not Sexually Active, Other Reason, 
Religion / Orthodox, Safety Concern / Side Effects, Time, Effectiveness Concern, and Not 
Needed or Not Necessary).   
 
3.4 Analytic Approach 
 We combined data from multiple survey years (2008-2012) using recommended methods 
(CDC, 2012).  Point estimates and their 95% confidence intervals (CIs) were weighted to be 
representative of the states from which they were actually sampled.  Bivariate analyses were 
used to describe the distribution across selected sociodemographic characteristics in each of the 
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three geographic categories.  T-tests were used to identify statistically significant differences. We 
considered differences with p-values of <0.05 as statistically significant. We also conducted a 
multivariable logistic regression model to produce adjusted prevalence ratios (APR) and 95% 
CIs. Statistical analysis was conducted using SAS callable SUDAAN release 11.0 (Research 
Triangle Institute, Research Triangle Park, NC) to account for the complex sampling design of 
the NIS-Teen data. All reported frequencies are unweighted. 
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CHAPTER IV 
RESULTS 
4.1 Demographic characteristics: 
In the DRA, adolescent females aged 13-17 years in NIS-Teen from 2008-2012 totaled 
1,903 compared to 4,997 in the Non-DRA counties and 40,809 in the rest of US (Table 1).  Over 
half (53%) in the DRA compared to 66% in the Non-DRA counties and 57% in the rest of US 
were Non-Hispanic whites, 41% compared to 18% in the Non-DRA counties and 14% in the rest 
of US were Non-Hispanic blacks and 3.5% compared to almost 11% in the Non-DRA counties 
and 21% in the rest of US were Hispanics.   
More than half of the mothers (53.8%) in the DRA compared to 60.2% in the Non-DRA 
counties and 60.4% in the rest of US had more than high school education and nearly 58% 
compared to 69.2% in the Non-DRA counties and 71.1% in the rest of USA were married.  Most 
of the mothers in the DRA were 35 years of age or older (about 83%) compared to 88.6% in the 
Non-DRA counties and 91% in the rest of US. 
About 83% of the teens in the DRA had a preventive care visit at 11 or 12 years of age 
compared to 87.6% in the Non-DRA counties and 87.6% in the rest of US.  Forty percent of the 
DRA households had income to poverty ratio (IPR) below 133% compared to about 29% in the 
Non-DRA and 28.8% in the rest of US; 32% of the DRA households had their IPR between 
133% and 322% compared to about 33% in the Non-DRA counties and 30.3% in the rest of US.  
In terms of vaccination payment sources, about 45% of the DRA households reported 
using Medicaid or Chip compared to 34% in the Non-DRA counties and 31.1% in the rest of US 
while 44% in the DRA used private providers as compared to 56% in the Non-DRA counties and 
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56% in the rest of US.  Six percent of the DRA were uninsured compared to 4% in the Non-DRA 
counties and 6.6% in the rest of US.  
Only 45% of the DRA parents reported receiving provider recommendation for HPV 
vaccination as compared to about 55% in the Non-DRA counties and about 58% in the rest of 
US.  About 88% of the DRA households reported knowing about the HPV vaccine compared to 
91% in the Non-DRA counties and about 91% in the rest of US.  Approximately 79% of DRA 
households said they had heard about HPV compared to about 84% in the Non-DRA counties 
and about 85% in the rest of US.  Forty-six percent of the DRA households reported having one 
provider compared to 51% in the Non-DRA counties and 54% in the rest of US but 37% of the 
DRA reported 2-3 vaccine providers compared to 32% in the Non-DRA counties and 30% in the 
rest of US.  
Sixty-one percent of the DRA reported having 2 or more contacts with a physician in the 
last year compared to 60% in the Non-DRA counties and 57% in the rest of US.  About 34% of 
the DRA households reported receipt of HPV vaccine at a private facility compared to 47% in 
the Non-DRA counties and about 57% in the rest of US, while 38% of the DRA received HPV 
vaccine at public facility compared to 23% in the Non-DRA counties and 16% in the rest of US.  
About 47% of the DRA sample lived in a rural area compared to 21% in the Non-DRA counties 
and 14% in the rest of US. 
 
4.2 HPV Initiation: 
About 41% (95%CI: 38.0-43.9) of adolescent females in the DRA had initiated HPV 
vaccination (Table 2).  Initiation increased from 25.3% in 2008 to 49.7% in 2012 with the only 
significant increase in coverage occurring the first year after the ACIP recommendation.  In 
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2008, participants in DRA were 30% less likely to have HPV initiation than participants in 2012.  
For Non-DRA counties, they were 24% less likely in 2008 and 19% less likely in 2009 compared 
to 2012 to have HPV initiation.  Trends were similar to Non-DRA counties for the rest of the US 
(Table 2).  
Significant disparities for HPV initiation were not identified for DRA counties compared 
to Non-DRA counties.  However, for Non-DRA counties, we found that those who were aged 13 
and 14 are about 20% less likely than 17 years olds to initiate HPV vaccination, for the rest of 
US, these differences are demonstrated for ages 13, 14 and 15 (Table 2).  Initiation of HPV 
vaccination did not vary by race among DRA and Non-DRA counties; however, for the rest of 
the US, Hispanics are 20% and people of other races are 11% more likely than Non-Hispanic 
Whites to initiate HPV vaccination.   
In the DRA, mothers with some college education are less likely than mothers with less 
than high school education to initiate HPV vaccination.  For the rest of the US, mothers with at 
least a high school education or greater were 20% less likely to initiate the HPV vaccination 
(Table 2).  Mothers’ age is a relevant factor for HPV initiation for the rest of the US; those 
whose mothers were aged 35 years or older were 10% less likely to initiate.  Teens in the DRA 
and rest of the US who did not have a preventive care visit at age 11or 12 years were less likely 
than those who had a preventive care visit to initiate HPV vaccination.  
In the Non-DRA counties, households with income to poverty ratio (IPR) between 322% 
and 503% were 14% less likely than those with IPR of 503% to initiate the HPV vaccination, 
while in the rest of the US, those between 133% and 322% were 14% and those between 322% 
and 503% were 6% less likely to initiate the HPV vaccination compared to this reference group.  
Adolescent females who used Medicaid or CHIP as their vaccination payment source were 37% 
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more likely to initiate HPV vaccination compared to those with a private provider in the DRA 
counties while in the rest of the US, they were 16% more likely to initiate HPV vaccination.  
Uninsured adolescent females in the rest of US were 11% less likely to do so.  For those who did 
not receive a provider recommendation for vaccination, they were all less likely to initiate HPV 
vaccination across all three geographic subgroups compared to those who did receive a provider 
recommendation (Table 2).  
Adolescent females with two or more total providers were less likely to initiate HPV 
vaccination in the rest of the US compared to those who had only one provider.  Association with 
number of physician contacts within the past year showed significance for some Non-DRA 
counties and in the Rest of the US (Table 2).  For facility type, in the DRA counties, adolescents 
who use public facility were 26% less likely than those who use private services to initiate HPV 
vaccination.  A similar pattern is seen for Non-DRA counties and the rest of the US among this 
group however, in the rest of the US, those who use mixed facilities are 7% more likely than 
those who use private services alone to initiate HPV vaccination.  Whereas there are no 
significant differences observed among people in urban and suburban areas compared to rural 
areas in the DRA and Non-DRA counties, for the rest of the US, they are all about 6-7% more 
likely than those in the rural areas to initiate HPV vaccination. 
 
4.3 Two or more HPV doses: 
The data indicate about 32% (95%CI: 28.8-34.4) of adolescent females in the DRA had 
received two or more doses of the HPV vaccination (Table 3).  Although 2+ HPV vaccination 
coverage was significantly higher in 2011 [40.0% (95% CI: 33.4-46.9)] than in 2008 [18.3% 
(95% CI: 13.7-24.1)] we found a decrease in coverage from 2011 to 2012 [37.3% (30.6 -44.6)]. 
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Results from the multivariable analyses in Table 3 reveal that coverage estimates for 2+ 
HPV vaccination doses is not different from that for HPV initiation for the population subgroups, 
with exception of adolescent females who are 15 years of age and those whose mothers are 35-44 
years of age.  The 15 year old adolescents had an APR of 1.26 (95% CI: 1.00-1.58; p-value 0.04) 
which is significantly higher 2+ HPV dose vaccination coverage than the referent group.  On the 
other hand, adolescent females with mothers 35-44 years of age had an APR of 0.71 (95% CI: 
0.55-0.90; p-value 0.01) which is significantly lower 2+ HPV dose vaccination coverage 
compared to the referent group (mothers ≤34 years of age).  
Race and ethnicity, mother’s education, mother’s marital status, number of total 
providers, number of physician contacts within the past year and MSA are not associated with 2+ 
HPV dose vaccination coverage in the DRA counties (Table 3).  Provider recommendation is 
still a very important determinant of 2+ HPV dose vaccinations; those who did not receive any 
provider recommendation are 55% less likely than those who did to have 2+ HPV dose 
vaccination.  However, people who use public facility are 32% less likely than people who use 
private services in the DRA to have 2+ HPV dose vaccinations. 
The data indicates about 31.7% (95% CI: 30.0-33.6) of adolescent females in the Non-
DRA counties had received two or more doses of the HPV vaccination (Table 3). Although 2+ 
HPV vaccination coverage was significantly higher in 2011 (i.e. 39.8% (95% CI: 35.5-44.3)) 
than in 2008 (i.e.  21.5% (95% CI: 18.1-25.2)), the data have not demonstrated significant annual 
increases. Results from the multivariable analyses in Table 3 reveal that coverage estimates for 
2+ HPV vaccination doses is not that different from that for HPV initiation for the population 
subgroups, with exception of adolescent females who used Medicaid or CHIP as their 
vaccination payment source, with an APR of 1.20 (95% CI: 1.02-1.41; p-value 0.03) which was 
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statistically significantly higher than their referent subgroup (those who used private sources of 
payment).  
 
4.4 Three or more HPV doses: 
In the DRA, about 23% (95%CI: 20.1-25.0) of the adolescent females had completed all 
of the recommended 3 doses of the HPV vaccination (Table 4).  Vaccination coverage estimates 
for 3+ HPV doses increased from 9.5% (95% CI: 6.8-13.2) in 2008 to 28.2% (95% CI: 22.2-
35.1) in 2012.  In the multivariate analysis, APR of 0.46 (95% CI: 0.30-0.69; p-value < 0.01) in 
2008 showed there was a significant increase compared with the coverage estimates in year 2012 
(i.e. reference level).  
We also observed an increase in coverage for both Non-DRA counties and in the rest of 
the US.  Adolescent females 14 years old with APR of 0.69 (95% CI: 0.49-0.98; p-value 0.04) 
were the only age group significantly less likely to be vaccinated compared to adolescent females 
17 years of age in the DRA (Table 4) according to the multivariate analysis.  However, for Non-
DRA counties, this decrease occurred in females aged 13 and 14 years and for the rest of US, 
females aged 13, 14, and 15 years were significantly less likely to have received ≥ 3 doses of 
HPV.   
Racial and ethnic differences for 3+ HPV vaccine uptakes are not demonstrated in DRA 
or Non-DRA counties, but blacks in the rest of the US were 12% less likely and Hispanics were 
9% more likely than whites to have received 3+ HPV vaccine doses.  The prevalence of 
adolescent females with 3+ HPV vaccine doses among those on Medicaid or CHIP (APR 1.64, 
95% CI: 1.21-2.22; p-value < 0.01) as their vaccinated payment source was statistically 
significantly higher than those who used private sources of payment from the multivariate 
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analysis.  Whereas vaccination payment source showed no differences in Non-DRA counties, in 
the rest of the US adolescent females who used Medicaid or CHIP were 15% more likely and the 
uninsured were 21% less likely than their counterparts who used private source as payment for 
vaccination to obtain 3+ vaccinations.  
Across all counties in the USA, provider recommendation is still a strong determinant of 
obtaining 3+ HPV dose vaccination uptakes (Table 4) and the use of public facilities is 
associated with lower likelihood of obtaining this compared to those who use private facilities. 
 
4.5 HPV Completion: 
Generally, 60.9% (95% CI: 55.8-65.8) of adolescent females in the DRA had completed 
the 3-dose HPV vaccination compared to 66.9% (95% CI: 63.7-70.0) of adolescent females in 
the Non-DRA counties and 67.6% in the rest of the USA.  In 2012, the prevalence ratio for DRA 
counties was significantly higher (62.7%) than it was in 2008 (43.2%); however, the rates have 
not demonstrated incremental improvements over time (Table 5).   
We did not observe age differences in completion for females in DRA.  However, for 
Non-DRA counties, females aged 13 years, and the rest of the US females aged 13 and 15 years 
were less likely to complete vaccination than females aged 17 years.  Adolescent females whose 
family IPR was less than 133% had an APR of 0.67 (95% CI: 0.50–0.89; p-value 0.01) and were 
less likely to have completed the 3- dose HPV vaccination than those with IPR of >503% in the 
DRA.  
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4.6 Intent and reasons for not intending to receive HPV vaccination: 
Among the teens without HPV vaccination, about 45% of their DRA parents reported a 
“very likely” or “somewhat likely” intent to receive the HPV vaccine compared to about 42% in 
the Non-DRA counties and about 40% in the rest of US.  The most common reasons for not 
intending to vaccinate in the DRA were belief that vaccination is unnecessary (23.6%, 95%CI: 
19.1-28.8), concerns about vaccine safety or side effects (18.2%, 95%CI: 14.4-22.8), indicating 
daughters were not sexually active (17.3%, 95%CI: 13.7-21.7), lack of knowledge about vaccine 
(16.6%, 95%CI: 12.7-21.3), and the vaccine not being recommended by the provider(12.1%, 
95%CI: 9.1-15.8) (Table 6). 
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CHAPTER V 
DISCUSSION AND CONCLUSION 
5.1 Discussion of Research Questions: 
Initiation 
Looking at factors associated with initiation of the HPV vaccine in DRA counties, public 
programs that provide vaccines are an important determinant for vaccine initiation.  Adolescents 
with Medicaid or CHIP had higher vaccine initiation rates compared to adolescents without.  In a 
research conducted by Keating, Brewer, Gottlieb, Liddon, Ludema, and Smith, (2008), most 
medical practitioners in high risk areas listed concerns about reimbursement for vaccine services 
provided, and cost to patients as well as the inconvenience of determining the insurance status of 
patients as barriers to vaccination.  
Additionally, individuals that use public facilities are less likely to initiate than those who 
use private facilities.  This scenario influenced the role of recommendation in these facilities for 
vaccine uptake.  We also found that adolescent females whose mothers were high school 
graduates were less likely to initiate HPV vaccination compared with those whose mothers had 
less than high school education.  The reasons underlying this situation may be complex and we 
are unable to explain it within the limits of our model.  
 
Two or more doses of HPV vaccination 
We found a decrease in vaccination rates for 2012 among DRA participants. Stokley, et 
al. (2013) point out that missed opportunities could be a major factor for decrease in receipt of 
one or more HPV vaccination, and that without any missed opportunities for HPV vaccination in 
2012, vaccination rates could have been as high as 92.6% in US.  Consequently, there could have 
been an increase in coverage in the DRA counties if they also had no missed opportunities for 
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HPV vaccination.  Brewer, Gottlieb, Reiter, Liddon, Markowitz, and Smith (2011) describe some 
missed opportunities in receiving HPV vaccine among adolescents in high risk areas as 
unrealized parent intentions and lack of doctor recommendations. 
Female adolescents aged 15 years were significantly more likely to receive two or more 
doses of HPV than those aged 17 years.  Adolescents whose mothers were aged 35-44 years at 
the time of report were less likely to receive two or more doses than adolescents whose mothers 
were younger.  These complex relationships need further investigation.  It may have 
socioeconomic factors or other reasons associated with its output.  
As expected, provider recommendations were associated with increases in 2+ HPV dose 
vaccinations for all three geographic areas of our study.  Adolescents who use public facilities 
also showed less likelihood of receiving two or more doses of HPV vaccination.  The issue with 
lower coverage of HPV vaccination in public facilities in 2012 may be associated with lack of 
recommendation for the vaccine, follow up or reminders or financing requirements (Brewer, et 
al. 2011; Fisher, et al. 2013; Rosenthal, Weiss, Zimet, Ma, Good, & Vichnin, 2011). 
 
Three or more doses of HPV vaccination 
Across the three geographic areas, female adolescents aged 14 years were less likely than 
those aged 17 years to receive three or more doses of HPV vaccination.  However, among the 
Non-DRA counties and the rest of US, those aged 13 years were also less likely than those aged 
17 years to receive three or more doses of HPV vaccination.  For the rest of the US, an 
increasing pattern was demonstrated in this uptake, even though we found that generally those 
younger than 17 years were less likely to have three or more doses of HPV vaccination, the 
magnitude of the point estimate increases with age (Table 4).  
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Indicators associated with higher likelihood of receiving three or more doses of HPV 
vaccination included a) having Medicaid or CHIP insurance; b) provider recommendation; and c) 
use of private facility.  In this study, we have found these factors to be consistently associated 
with improved vaccine uptake. 
 
HPV completion 
In the DRA, adolescents whose family IPR was less than 133% were less likely to have 
completed the 3 dose HPV vaccination series than those with IPR of >503%, which could be an 
affordability issues. 
 
Intent and reasons for not intending to receive HPV vaccination 
Several reasons account for non-receipt of HPV vaccination.  Among them, we explored 
the following in high-to-low ranking order in the DRA: a) belief that vaccination is unnecessary; 
b) concerns about vaccine safety, or side effects; c) lack of knowledge about vaccine; d) 
indicating daughters were not sexually active; and e) the vaccine not being recommended by the 
provider.  These same reasons were also noted for Non-DRA counties and the rest of US, 
however the order was different.  For example, in the Non-DRA counties, belief that adolescent 
daughters were not sexually active ranked second after belief that vaccination is unnecessary, 
followed by lack of knowledge, vaccine safety concerns and lack of recommendation.  
In the rest of US, the high-low ranking was as follows: a) not being sexually active; b) 
lack of knowledge; c) belief that vaccination was unnecessary; d) lack of recommendation; and 
e) safety concerns about the vaccine.  These rankings can be priority areas of concern that can be 
tailored to specific geographic areas in education on HPV vaccination.   
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The finding that across all geographic areas, belief that HPV vaccination is unnecessary 
shows that there is the need to educate the general public on the risks of HPV infection and 
benefits of HPV vaccination, especially among the youth to prevent cervical cancer and any 
sequelae from the infection.  Dempsey and others conducted a qualitative study and examined 
factors stated by the mothers of adolescents for not vaccinating their female adolescents against 
HPV.  They list the importance of educating parents and addressing their safety concerns about 
HPV vaccination as well as the promotion of strong physician HPV vaccine recommendation 
(Dempsey, Cohn, Dalton, & Ruffin, 2011). 
Compared to Non-DRA counties and the rest of the US, a lower rate of provider 
recommendations was reported in the DRA.  This is an important observation concerning the 
lower rates of vaccination demonstrated in the DRA; since provider recommendation is 
associated with higher vaccination uptake (Rosenthal et al., 2013; Ylitalo, et al. 2013), this is an 
area for improvement in the DRA.  It is important to encourage providers to make strong 
recommendations for HPV vaccinations to help protect females from HPV as well as improve 
rates of vaccination in the DRA.  As participants from the DRA were found to have more 
physician contacts than participants from other areas, physicians could be an important factor for 
helping to increase vaccination in these areas; they must be encouraged to recommend the HPV 
vaccination. 
The observation that there is a lower knowledge rate for HPV awareness and HPV 
vaccine in the DRA than the other two geographic areas of study implies that education on HPV 
must be improved in the DRA.  Healthcare personnel must be trained and encouraged to help 
with this aspect.  The thought that more parents in the DRA expressed intent to vaccinate than 
Non-DRA counties and the rest of US shows a possibility of increasing HPV vaccination through 
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awareness and improving other programs that increase opportunities, availability and 
accessibility to HPV vaccination processes. 
Further challenges facing the DRA include the observation that less people in the DRA 
reported having single providers than the other two geographic areas in our study.  This may be a 
contributory factor to lower coverage or vaccine receipt.  This is because research shows that 
people who have single providers are more likely to initiate vaccination but also to complete 
vaccination schedules.  The medical histories remain with an individual health care provider and 
are followed up or reminded when vaccinations are due.  Those who have several health care 
providers, however, may have their medical histories dispersed and follow-up may be difficult.  
The public facility is a major center for vaccine receipt in the DRA, whereas the Non-
DRA counties and rest of the US use more private institutions for their vaccination.  It is 
important to equip the public institution with logistics to recommend and provide vaccinations.  
It appears that individuals use fewer private institutions because of affordability (Fisher, et al. 
2013).  If there could be federally qualified private institutions to help provide vaccinations, then 
this could also improve vaccine uptake.  Dempsey and others discuss how disparities in health 
care utilization affect HPV vaccination and noted the lack of insurance as one of the contributing 
factors non-vaccination exist among comparatively older women aged 19 – 26 years old 
(Dempsey, et al. 2011). 
The observation that most of the DRA participants live in rural areas could mean they 
have vaccine accessibility challenges even though for certain populations’ access may not be a 
factor (Gelman, et al. 2013).  In other circumstances, distance reduces access to vaccination sites 
if the rural areas are not equipped with centers to provide vaccinations.  It is important to equip 
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healthcare centers in rural areas with HPV vaccination opportunities if this is lacking to increase 
access (Dorell, Yankey, Santibanez, & Markowitz, 2011). 
 
5.2 Study Strengths and Limitations 
The strength of this study can be attributed to the fact that the NIS-Teen is provider-
verified vaccination data. We combined multiple years of data to increase our sample size and 
this also increased the power of our results.  Although the NIS-Teen was previously limited to 
household with landline telephones only, we had in our data set two years which included cell-
phone sampling frames.  This was instrumental in increasing the representativeness of the data 
for the target population.  Incomplete provider vaccination records and not having community-
level or county-level factors that might influence HPV vaccination could be a limitation in our 
study. Nonetheless, we believe the use of our findings could help inform providers and policy 
makers in the DRA to find ways to increase HPV vaccination.    
 
5.3 Conclusion and Recommendation 
We found that the DRA showed lower HPV vaccine initiation and completion compared 
to Non-DRA counties and the rest of US.  There are disparities in vaccine initiation and 
completion across the geographic areas of study, which probably suggests the unique socio-
demographic properties of the areas.  Provider recommendations and awareness are important for 
increasing HPV vaccine uptake.  Insurance and financing programs help with HPV vaccine 
uptake and are encouraged for the DRA.  Individuals that use private facilities were more likely 
to initiate and complete HPV vaccination than those who use public facilities; this relationship 
requires further exploratory research.  The low vaccination coverage among adolescents in these 
 30 
 
areas shows that it is important to implement additional prevention strategies to reduce cancers 
associated with HPV in the Delta Region.  
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Table 1. Characteristics of adolescent females aged 13-17 years by age at interview, National Immunization Survey-Teen, United States, 2008 - 2012 
Sociodemographic Characteristics 
United States 
Delta Regional Authority States (DRA) 
Rest of US 
DRA Counties Non-DRA Counties 
n 
Weighted 
Proportion % 
(95% C.I.) 
n 
Weighted 
Proportion % 
(95% C.I.) 
n 
Weighted 
Proportion % 
(95% C.I.) 
n 
Weighted 
Proportion % 
(95% C.I.) 
Year 47,709 100.0 (---------) 1,903 100.0 (---------) 4,997 100.0 (---------) 40,809 100.0 (---------) 
2008 8,600 20.3 (19.7-20.9) 400 20.6 (18.4-22.8) 1,003 20.3 (18.9-21.7) 7,197 20.3 (19.6-21.0) 
2009 9,614 20.0 (19.5-20.6) 361 19.7 (17.6-22.0) 1,042 20.2 (18.9-21.5) 8,211 20.0 (19.4-20.6) 
2010 9,214 19.7 (19.2-20.2) 366 20.9 (18.8-23.1) 925 19.4 (18.2-20.6) 7,923 19.7 (19.1-20.3) 
2011 11,228 20.0 (19.5-20.6) 404 19.8 (17.7-22.2) 1,124 20.0 (18.7-21.4) 9,700 20.1 (19.5-20.6) 
2012 9,053 19.9 (19.4-20.5) 372 19.0 (16.7-21.6) 903 20.2 (18.8-21.7) 7,778 19.9 (19.3-20.6) 
         
Age of Teen (years) 47,709 100.0 (---------) 1,903 100.0 (---------) 4,997 100.0 (---------) 40,809 100.0 (---------) 
13 9,523 19.6 (18.9-20.2) 413 21.3 (18.9-23.8) 1,010 20.3 (18.8-21.9) 8,100 19.4 (18.7-20.1) 
14 9,813 19.8 (19.1-20.5) 417 20.4 (18.2-22.8) 1,022 19.0 (17.5-20.5) 8,374 19.9 (19.1-20.6) 
15 9,802 21.2 (20.5-21.9) 358 19.0 (16.8-21.4) 1,071 22.2 (20.6-23.8) 8,373 21.2 (20.4-22.0) 
16 9,732 20.6 (19.9-21.3) 387 20.9 (18.4-23.5) 992 20.5 (18.9-22.1) 8,353 20.6 (19.8-21.4) 
17 8,839 18.8 (18.2-19.5) 328 18.5 (16.3-21.0) 902 18.1 (16.7-19.6) 7,609 18.9 (18.2-19.7) 
         
Race / ethnicity 47,709 100.0 (---------) 1,903 100.0 (---------) 4,997 100.0 (---------) 40,809 100.0 (---------) 
White, non-Hispanic 32,689 57.9 (57.1-58.8) 1,200 52.6 (49.5-55.6) 3,510 66.3 (64.3-68.2) 27,979 57.1 (56.2-58.1) 
Black, non-Hispanic 4,973 14.9 (14.3-15.6) 573 40.6 (37.6-43.7) 739 17.6 (16.0-19.3) 3,661 13.7 (13.0-14.4) 
Hispanic 6,137 19.4 (18.6-20.2) 60 3.5 (2.5-4.9) 479 10.6 (9.3-12.1) 5,598 20.9 (20.1-21.8) 
Other 3,910 7.8 (7.3-8.3) 70 3.4 (2.5-4.5) 269 5.5 (4.6-6.5) 3,571 8.2 (7.7-8.8) 
         
Mother's Education 47,709 100.0 (---------) 1,903 100.0 (---------) 4,997 100.0 (---------) 40,809 100.0 (---------) 
<High school 4,539 13.8 (13.2-14.5) 206 14.1 (12.0-16.5) 509 12.0 (10.7-13.4) 3,824 14.0 (13.3-14.8) 
High school graduates 9,402 26.0 (25.2-26.8) 507 32.1 (29.3-35.0) 1,098 27.8 (26.0-29.7) 7,797 25.5 (24.7-26.4) 
> High school graduate, some college 13,738 26.6 (25.9-27.3) 545 27.9 (25.2-30.7) 1,492 27.6 (25.9-29.3) 11,701 26.4 (25.7-27.2) 
College graduate 20,030 33.6 (32.9-34.3) 645 25.9 (23.7-28.3) 1,898 32.6 (30.9-34.4) 17,487 34.0 (33.2-34.8) 
         
Mother's marital status 47,287 100.0 (---------) 1,878 100.0 (---------) 4,942 100.0 (---------) 40,467 100.0 (---------) 
Married 35,854 70.5 (69.7-71.3) 1,279 57.7 (54.6-60.7) 3,666 69.2 (67.3-71.1) 30,909 71.1 (70.2-72.0) 
Divorced / Widowed / Separated 8,038 20.1 (19.4-20.8) 401 25.4 (22.8-28.2) 870 21.8 (20.1-23.6) 6,767 19.7 (18.9-20.5) 
Never Married 3,395 9.4 (8.9-10.0) 198 16.9 (14.4-19.8) 406 9.0 (7.8-10.3) 2,791 9.2 (8.6-9.8) 
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Table 1. Characteristics of adolescent females aged 13-17 years by age at interview, National Immunization Survey-Teen, United States, 2008 - 2012 
Sociodemographic Characteristics 
United States 
Delta Regional Authority States (DRA) 
Rest of US 
DRA Counties Non-DRA Counties 
n 
Weighted 
Proportion % 
(95% C.I.) 
n 
Weighted 
Proportion % 
(95% C.I.) 
n 
Weighted 
Proportion % 
(95% C.I.) 
n 
Weighted 
Proportion % 
(95% C.I.) 
Mother's Age (years) 47,709 100.0 (---------) 1,903 100.0 (---------) 4,997 100.0 (---------) 40,809 100.0 (---------) 
≤34 years 3,514 9.4 (8.9-10.0) 228 16.9 (14.5-19.6) 445 11.5 (10.1-13.0) 2,841 8.9 (8.4-9.5) 
35–44 years 19,975 45.5 (44.7-46.4) 883 48.4 (45.5-51.5) 2,246 47.1 (45.1-49.0) 16,846 45.2 (44.3-46.2) 
≥45 years 24,220 45.0 (44.2-45.9) 792 34.7 (32.0-37.4) 2,306 41.5 (39.6-43.4) 21,122 45.8 (44.9-46.7) 
         
Teen had a preventive care visit at age 11 or 12  years 47,217 100.0 (---------) 1,866 100.0 (---------) 4,943 100.0 (---------) 40,408 100.0 (---------) 
Yes visit 41,572 87.4 (86.8-88.0) 1,515 82.6 (80.3-84.6) 4,294 87.6 (86.3-88.8) 35,763 87.6 (86.9-88.2) 
No visit 5,645 12.6 (12.0-13.2) 351 17.4 (15.4-19.7) 649 12.4 (11.2-13.7) 4,645 12.4 (11.8-13.1) 
         
Income to poverty ratio 47,709 100.0 (---------) 1,903 100.0 (---------) 4,997 100.0 (---------) 40,809 100.0 (---------) 
<133% 9,871 29.1 (28.3-29.9) 565 39.6 (36.5-42.7) 1,169 28.8 (26.9-30.7) 8,137 28.8 (27.8-29.7) 
133% - <322% 14,574 30.6 (29.9-31.4) 579 31.8 (29.1-34.6) 1,617 32.8 (31.0-34.6) 12,378 30.3 (29.5-31.2) 
322% - <503% 11,227 19.7 (19.1-20.4) 399 15.3 (13.6-17.1) 1,158 21.3 (19.8-22.8) 9,670 19.7 (19.1-20.4) 
>503% 12,037 20.5 (19.9-21.2) 360 13.4 (11.8-15.1) 1,053 17.2 (15.9-18.5) 10,624 21.2 (20.5-21.9) 
         
Vaccination payment source 47,589 100.0 (---------) 1,901 100.0 (---------) 4,986 100.0 (---------) 40,702 100.0 (---------) 
Private Only 29,716 55.6 (54.8-56.5) 981 43.6 (40.7-46.5) 3,029 56.1 (54.1-58.0) 25,706 56.0 (55.0-56.9) 
Medicaid / CHIP  11,728 31.8 (31.0-32.6) 694 45.2 (42.1-48.2) 1,446 34.0 (32.1-36.0) 9,588 31.1 (30.1-32.0) 
Uninsured 2,249 6.3 (5.8-6.8) 108 6.1 (4.9-7.6) 180 4.0 (3.3-4.8) 1,961 6.6 (6.0-7.1) 
Military 1,143 2.0 (1.8-2.2) 35 1.8 (1.2-2.9) 90 1.8 (1.4-2.4) 1,018 2.0 (1.8-2.3) 
Other / IHS / AIAN(All) 2,753 4.3 (4.0-4.6) 83 3.3 (2.5-4.2) 241 4.1 (3.5-4.9) 2,429 4.4 (4.0-4.7) 
         
Received provider recommendation for HPV vaccination 46,089 100.0 (---------) 1,835 100.0 (---------) 4,820 100.0 (---------) 39,434 100.0 (---------) 
Yes 27,735 57.0 (56.1-57.8) 883 45.0 (42.0-48.0) 2,674 54.5 (52.5-56.4) 24,178 57.7 (56.7-58.6) 
No 18,354 43.0 (42.2-43.9) 952 55.0 (52.0-58.0) 2,146 45.5 (43.6-47.5) 15,256 42.3 (41.4-43.3) 
         
Knowledge about HPV Vaccine 38,297 100.0 (---------) 1,513 100.0 (---------) 4,043 100.0 (---------) 32,741 100.0 (---------) 
Yes 36,043 91.1 (90.4-91.8) 1,385 88.3 (85.7-90.4) 3,768 91.3 (89.9-92.6) 30,890 91.2 (90.3-91.9) 
No 2,254 8.9 (8.2-9.6) 128 11.7 (9.6-14.3) 275 8.7 (7.4-10.1) 1,851 8.8 (8.1-9.7) 
         
Heard about HPV vaccine 38,070 100.0 (---------) 1,505 100.0 (---------) 4,015 100.0 (---------) 32,550 100.0 (---------) 
Yes 33,256 84.3 (83.5-85.1) 1,236 79.3 (76.5-81.9) 3,448 83.8 (82.1-85.5) 28,572 84.5 (83.6-85.4) 
No 4,814 15.7 (14.9-16.5) 269 20.7 (18.1-23.5) 567 16.2 (14.5-17.9) 3,978 15.5 (14.6-16.4) 
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Table 1. Characteristics of adolescent females aged 13-17 years by age at interview, National Immunization Survey-Teen, United States, 2008 - 2012 
Sociodemographic Characteristics 
United States 
Delta Regional Authority States (DRA) 
Rest of US 
DRA Counties Non-DRA Counties 
n 
Weighted 
Proportion % 
(95% C.I.) 
n 
Weighted 
Proportion % 
(95% C.I.) 
n 
Weighted 
Proportion % 
(95% C.I.) 
n 
Weighted 
Proportion % 
(95% C.I.) 
         
Number of Total Providers 47,709 100.0 (---------) 1,903 100.0 (---------) 4,997 100.0 (---------) 40,809 100.0 (---------) 
1 24,471 53.0 (52.2-53.8) 856 45.9 (42.9-48.9) 2,528 50.7 (48.7-52.6) 21,087 53.5 (52.6-54.4) 
2 - 3 14,679 30.0 (29.2-30.8) 704 37.4 (34.5-40.4) 1,607 31.8 (30.0-33.6) 12,368 29.5 (28.7-30.4) 
4 or more 8,559 17.0 (16.4-17.7) 343 16.6 (14.6-18.9) 862 17.5 (16.1-19.1) 7,354 17.0 (16.3-17.7) 
         
Physician contacts within past year 47,403 100.0 (---------) 1,885 100.0 (---------) 4,962 100.0 (---------) 40,556 100.0 (---------) 
None  6,782 16.2 (15.6-16.9) 268 17.2 (14.9-19.7) 666 14.6 (13.2-16.0) 5,848 16.4 (15.7-17.1) 
1 12,371 26.3 (25.5-27.0) 429 22.0 (19.7-24.5) 1,248 25.0 (23.4-26.7) 10,694 26.5 (25.7-27.4) 
2 - 3 17,571 36.4 (35.6-37.2) 699 36.1 (33.3-39.1) 1,892 37.6 (35.7-39.5) 14,980 36.3 (35.4-37.2) 
4 or more 10,679 21.1 (20.5-21.8) 489 24.7 (22.2-27.4) 1,156 22.9 (21.3-24.5) 9,034 20.8 (20.1-21.5) 
         
Facility Type 47,581 100.0 (---------) 1,900 100.0 (---------) 4,981 100.0 (---------) 40,700 100.0 (---------) 
Private 24,723 55.1 (54.3-55.9) 644 33.5 (30.8-36.4) 2,350 47.3 (45.3-49.2) 21,729 56.8 (55.9-57.7) 
Public 8,211 17.5 (16.9-18.2) 665 37.7 (34.8-40.7) 1,173 22.8 (21.3-24.5) 6,373 16.2 (15.5-16.9) 
Hospital 3,965 7.2 (6.8-7.6) 117 6.2 (5.0-7.8) 324 7.4 (6.4-8.6) 3,524 7.2 (6.8-7.7) 
Mixed 9,158 17.1 (16.5-17.7) 436 20.7 (18.5-23.1) 994 19.6 (18.1-21.1) 7,728 16.6 (16.0-17.3) 
Other 1,524 3.1 (2.8-3.4) 38 1.8 (1.2-2.6) 140 3.0 (2.4-3.7) 1,346 3.2 (2.8-3.5) 
         
MSA 47,709 100.0 (---------) 1,903 100.0 (---------) 4,997 100.0 (---------) 40,809 100.0 (---------) 
Urban area 18,592 38.9 (38.1-39.7) 436 25.3 (22.7-28.2) 1,941 32.8 (31.1-34.5) 16,215 40.1 (39.2-41.0) 
Suburban area  18,049 45.0 (44.2-45.9) 568 27.3 (24.8-29.9) 1,936 46.7 (44.8-48.7) 15,545 45.5 (44.5-46.4) 
Rural area 11,068 16.1 (15.6-16.6) 899 47.4 (44.4-50.3) 1,120 20.5 (19.1-22.0) 9,049 14.4 (13.9-15.0) 
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Table 2. Unadjusted and Adjusted (Multivariate) logistic regression analysis for 1+ HPV vaccination coverage estimates among adolescent females aged 13-17 years by age at interview for 
selected sociodemographic characteristics, National Immunization Survey-Teen, United States, 2008 - 2012 
Sociodemographic 
Characteristics 
United States 
Delta Regional Authority States (DRA) 
Rest of US 
DRA Counties Non-DRA Counties 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)        
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)   
 % (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
             
Total 47.4 (46.6-48.2)   40.9 (38.0-43.9)   40.0 (38.1-41.9)   48.5 (47.6-49.4)*   
Year             
2008 37.2 (35.2-39.3)† 0.80 (0.76-0.85) 0.00 25.3 (20.1-31.3)† 0.70 (0.54-0.89) 0.00 28.9 (25.2-33.0)† 0.76 (0.65-0.88) 0.00 38.6 (36.3-41.0)*† 0.81 (0.76-0.87) 0.00 
2009 44.3 (42.4-46.1)† 0.90 (0.85-0.95) 0.00 40.2 (33.7-47.0) 0.89 (0.72-1.09) 0.26 34.6 (30.9-38.4)† 0.81 (0.70-0.93) 0.00 45.6 (43.5-47.6)† 0.91 (0.86-0.96) 0.00 
2010 48.7 (46.9-50.6)† 0.99 (0.94-1.04) 0.64 41.2 (35.4-47.3) 0.97 (0.80-1.19) 0.80 39.7 (36.0-43.7)† 0.94 (0.82-1.07) 0.35 50.1 (48.0-52.1)*† 0.99 (0.94-1.05) 0.82 
2011 53.1 (51.4-54.7) 1.03 (0.99-1.08) 0.16 48.9 (42.1-55.7) 1.04 (0.84-1.29) 0.69 48.8 (44.4-53.1) 1.04 (0.91-1.18) 0.60 53.7 (51.9-55.5) 1.03 (0.98-1.09) 0.22 
2012 53.9 (52.0-55.7) ref  49.7 (42.2-57.3) ref  47.9 (43.2-52.7) ref  54.7 (52.7-56.8) ref  
             
Age of Teen (years)             
13 40.0 (38.3-41.8)† 0.76 (0.72-0.80) 0.00 37.9 (31.9-44.4) 0.87 (0.70-1.10) 0.25 33.5 (29.6-37.7)† 0.80 (0.69-0.93) 0.00 40.9 (39.0-42.9)† 0.75 (0.71-0.80) 0.00 
14 43.5 (41.7-45.3)† 0.83 (0.78-0.87) 0.00 37.5 (31.7-43.7) 0.93 (0.76-1.14) 0.49 37.4 (33.2-41.7) 0.82 (0.71-0.95) 0.01 44.4 (42.4-46.5)*† 0.82 (0.78-0.87) 0.00 
15 49.9 (48.0-51.8)† 0.93 (0.89-0.98) 0.00 48.3 (41.6-55.0) 1.15 (0.95-1.39) 0.15 42.2 (38.2-46.3) 0.96 (0.85-1.09) 0.55 50.9 (48.8-53.0)† 0.92 (0.88-0.97) 0.00 
16 50.6 (48.7-52.5) 0.96 (0.91-1.01) 0.09 40.8 (34.2-47.7) 1.02 (0.84-1.23) 0.85 44.2 (39.8-48.6) 1.02 (0.90-1.16) 0.73 51.7 (49.6-53.8)* 0.95 (0.90-1.00) 0.07 
17 52.8 (50.8-54.8) ref  40.6 (33.8-47.7) ref  42.3 (37.9-46.9) ref  54.4 (52.2-56.6)* ref  
             
Race / ethnicity             
White, non-Hispanic 44.5 (43.6-45.4) ref  37.0 (33.5-40.6) ref  38.8 (36.7-41.0) ref  45.5 (44.5-46.5)* ref  
Black, non-Hispanic 46.9 (44.5-49.3) 0.99 (0.93-1.05) 0.64 44.9 (39.7-50.2)† 1.01 (0.86-1.18) 0.94 41.6 (36.5-46.8) 1.00 (0.87-1.16) 0.98 47.9 (45.1-50.8) 0.98 (0.92-1.05) 0.58 
Hispanic 55.5 (53.1-57.9)† 1.21 (1.15-1.27) 0.00 49.9 (33.4-66.4) 1.11 (0.79-1.56) 0.56 44.9 (38.0-52.1) 1.12 (0.94-1.33) 0.22 56.2 (53.6-58.7)† 1.20 (1.14-1.27) 0.00 
Other 49.8 (46.6-53.0)† 1.11 (1.04-1.18) 0.00 43.7 (30.3-58.0) 1.05 (0.77-1.43) 0.76 39.1 (31.2-47.7) 1.00 (0.83-1.21) 0.99 50.7 (47.2-54.1)† 1.11 (1.03-1.18) 0.00 
             
Mother's Education             
<High school 54.7 (52.0-57.4) ref  49.6 (40.9-58.4) ref  40.6 (34.6-46.9) ref  56.3 (53.3-59.2) ref  
High school graduates 46.6 (44.7-48.4)† 0.88 (0.83-0.94) 0.00 40.7 (35.4-46.2) 0.86 (0.69-1.06) 0.17 40.2 (36.3-44.3) 1.06 (0.88-1.27) 0.54 47.7 (45.6-49.7)*† 0.87 (0.81-0.93) 0.00 
> High school graduate, some college 45.6 (44.1-47.1)† 0.86 (0.81-0.91) 0.00 37.7 (32.1-43.6)† 0.78 (0.63-0.97) 0.03 38.1 (34.7-41.5) 0.97 (0.81-1.17) 0.75 46.8 (45.1-48.5)*† 0.85 (0.80-0.91) 0.00 
College graduate 46.5 (45.2-47.7)† 0.85 (0.80-0.91) 0.00 39.9 (35.3-44.7) 0.82 (0.65-1.03) 0.10 41.1 (38.1-44.2) 1.05 (0.86-1.27) 0.65 47.2 (45.9-48.6)*† 0.84 (0.78-0.90) 0.00 
             
Mother's marital status             
Married 45.4 (44.5-46.4) ref  36.2 (32.9-39.6) ref  39.0 (36.8-41.1) ref  46.4 (45.4-47.5)* ref  
Divorced / Widowed / Separated 50.1 (48.1-52.0)† 1.03 (0.98-1.08) 0.21 43.7 (37.7-50.0)† 1.10 (0.93-1.30) 0.28 40.6 (36.1-45.2) 0.94 (0.83-1.07) 0.37 51.6 (49.3-53.8)*† 1.04 (0.99-1.10) 0.12 
Never Married 56.1 (53.0-59.2)† 1.09 (1.01-1.17) 0.03 52.8 (43.8-61.7)† 1.17 (0.93-1.47) 0.20 46.8 (39.6-54.1)† 1.11 (0.93-1.32) 0.28 57.4 (53.8-60.8)† 1.08 (1.00-1.17) 0.06 
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Table 2. Unadjusted and Adjusted (Multivariate) logistic regression analysis for 1+ HPV vaccination coverage estimates among adolescent females aged 13-17 years by age at interview for 
selected sociodemographic characteristics, National Immunization Survey-Teen, United States, 2008 - 2012 
Sociodemographic 
Characteristics 
United States 
Delta Regional Authority States (DRA) 
Rest of US 
DRA Counties Non-DRA Counties 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)        
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)   
 % (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
             
Mother's Age (years)             
≤34 years 53.9 (50.9-56.8) ref  48.9 (40.5-57.4) ref  44.6 (38.0-51.3) ref  55.6 (52.1-59.0) ref  
35–44 years 46.5 (45.2-47.8)† 0.90 (0.85-0.96) 0.00 37.3 (33.2-41.6)† 0.83 (0.67-1.02) 0.09 39.4 (36.6-42.3) 0.91 (0.78-1.07) 0.27 47.7 (46.2-49.2)*† 0.90 (0.84-0.97) 0.01 
≥45 years 47.0 (45.8-48.1)† 0.89 (0.84-0.95) 0.00 42.0 (37.7-46.5) 0.94 (0.76-1.16) 0.57 39.3 (36.6-42.1) 0.90 (0.76-1.06) 0.21 47.9 (46.6-49.2)*† 0.89 (0.82-0.95) 0.00 
             
Teen had a preventive care visit at age 11 
or 12  years             
Yes visit 49.2 (48.3-50.1) ref  44.7 (41.4-48.1) ref  41.4 (39.4-43.5) ref  50.3 (49.3-51.3)* ref  
No visit 37.4 (34.9-39.9)† 0.92 (0.87-0.98) 0.01 26.1 (20.8-32.2)† 0.78 (0.64-0.94) 0.01 31.1 (26.4-36.4)† 1.03 (0.89-1.18) 0.70 38.7 (35.9-41.5)*† 0.92 (0.86-0.98) 0.01 
             
Income to poverty ratio             
<133% 54.3 (52.5-56.1)† 1.00 (0.94-1.07) 0.96 50.1 (44.7-55.5) 1.03 (0.81-1.31) 0.80 44.9 (40.9-49.0) 1.09 (0.92-1.28) 0.31 55.6 (53.6-57.6)† 0.99 (0.92-1.06) 0.80 
133% - <322% 41.6 (40.2-43.0)† 0.86 (0.82-0.90) 0.00 30.6 (26.0-35.6)† 0.84 (0.68-1.02) 0.08 35.6 (32.4-38.8)† 0.91 (0.80-1.04) 0.17 42.8 (41.1-44.4)*† 0.86 (0.81-0.90) 0.00 
322% - <503% 43.5 (41.9-45.1)† 0.91 (0.87-0.95) 0.00 37.9 (32.4-43.6) 0.91 (0.76-1.09) 0.30 35.7 (32.2-39.4)† 0.86 (0.76-0.98) 0.02 44.6 (42.9-46.4)† 0.92 (0.88-0.97) 0.00 
>503% 50.0 (48.3-51.7) ref  41.7 (35.5-48.1) ref  45.3 (41.3-49.4) ref  50.7 (48.8-52.5)* ref  
             
Vaccination payment source             
Private Only 44.1 (43.1-45.1) ref  32.4 (28.7-36.3) ref  38.2 (35.9-40.5)* ref  45.1 (44.0-46.3)* ref  
Medicaid / CHIPS  55.8 (54.2-57.5)† 1.16 (1.10-1.22) 0.00 51.5 (46.6-56.4)† 1.37 (1.12-1.67) 0.00 44.7 (41.0-48.5)*† 1.09 (0.96-1.25) 0.18 57.5 (55.6-59.3)*† 1.16 (1.09-1.23) 0.00 
Uninsured 35.3 (31.8-39.0)† 0.91 (0.82-1.01) 0.07 25.0 (16.7-35.7) 1.01 (0.72-1.44) 0.94 26.0 (18.5-35.3)† 0.99 (0.78-1.27) 0.95 36.3 (32.5-40.3)*† 0.89 (0.80-1.00) 0.04 
Military 44.7 (39.1-50.4) 0.98 (0.88-1.11) 0.79 35.2 (18.2-56.9) 1.22 (0.80-1.88) 0.39 46.9 (32.9-61.4) 1.23 (0.93-1.63) 0.19 44.8 (38.7-51.0) 0.95 (0.84-1.08) 0.41 
Other / IHS / AIAN(All) 46.7 (43.0-50.3) 1.01 (0.93-1.09) 0.86 40.5 (28.9-53.2) 1.02 (0.73-1.42) 0.91 36.7 (28.9-45.3) 0.89 (0.72-1.11) 0.29 47.9 (43.9-52.0) 1.01 (0.92-1.11) 0.81 
             
Received provider recommendation for 
HPV vaccination             
Yes 61.5 (60.4-62.6) ref  58.9 (54.7-63.0) ref  56.2 (53.6-58.8) ref  62.2 (61.0-63.3) ref  
No 28.9 (27.6-30.2)† 0.49 (0.47-0.51) 0.00 25.4 (21.7-29.4)† 0.48 (0.41-0.57) 0.00 21.1 (18.8-23.5)† 0.40 (0.35-0.45) 0.00 30.0 (28.6-31.5)*† 0.50 (0.48-0.53) 0.00 
             
Do you know about HPV Vaccine  NA   NA   NA   NA  
Yes 47.0 (46.1-48.0)   39.4 (36.1-42.7)   39.9 (37.7-42.0)   48.1 (47.1-49.2)*   
No 34.0 (29.9-38.4)†   31.9 (22.4-43.3)   20.0 (14.4-27.2)†   35.7 (31.1-40.7)†   
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Table 2. Unadjusted and Adjusted (Multivariate) logistic regression analysis for 1+ HPV vaccination coverage estimates among adolescent females aged 13-17 years by age at interview for 
selected sociodemographic characteristics, National Immunization Survey-Teen, United States, 2008 - 2012 
Sociodemographic 
Characteristics 
United States 
Delta Regional Authority States (DRA) 
Rest of US 
DRA Counties Non-DRA Counties 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)        
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)   
 % (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Have you heard about HPV vaccine  NA   NA   NA   NA  
Yes 46.8 (45.8-47.8)   39.8 (36.3-43.5)   39.3 (37.1-41.6)   47.9 (46.8-49.0)*   
No 40.9 (38.1-43.8)†   33.0 (26.6-40.1)   31.5 (26.5-37.0)†   42.4 (39.2-45.7)*†   
             
Number of Total Providers             
1 48.0 (46.9-49.2) ref  41.5 (37.3-45.9) ref  39.9 (37.2-42.6) ref  49.1 (47.8-50.4)* ref  
2 - 3 45.5 (44.0-47.0)† 0.92 (0.88-0.95) 0.00 38.0 (33.2-42.9) 0.91 (0.78-1.07) 0.27 38.0 (34.8-41.3) 0.94 (0.85-1.05) 0.26 46.8 (45.0-48.5)*† 0.92 (0.88-0.96) 0.00 
4 or more 48.9 (46.9-50.9) 0.91 (0.86-0.96) 0.00 45.8 (38.8-52.9) 0.97 (0.80-1.18) 0.76 43.8 (39.1-48.5) 0.95 (0.82-1.08) 0.42 49.6 (47.3-51.8) 0.91 (0.86-0.96) 0.00 
             
Physician contacts within past year             
None  34.9 (32.9-37.1)† 0.77 (0.73-0.83) 0.00 31.7 (24.9-39.3)† 0.83 (0.67-1.03) 0.09 27.1 (22.8-31.9)† 0.75 (0.63-0.90) 0.00 35.9 (33.6-38.2)† 0.77 (0.72-0.83) 0.00 
1 44.9 (43.3-46.5)† 0.89 (0.85-0.93) 0.00 41.3 (35.4-47.4) 1.02 (0.85-1.21) 0.84 38.3 (34.7-42.1) 1.01 (0.90-1.14) 0.85 45.7 (43.9-47.5)† 0.87 (0.83-0.91) 0.00 
2 - 3 50.4 (49.0-51.8)† 0.95 (0.91-0.99) 0.01 41.0 (36.1-46.0) 0.88 (0.75-1.02) 0.10 43.6 (40.4-46.9) 1.02 (0.91-1.14) 0.77 51.6 (50.0-53.1)*† 0.94 (0.90-0.98) 0.01 
4 or more 54.6 (52.9-56.3) ref  46.8 (40.7-52.9) ref  43.8 (39.9-47.7) ref  56.3 (54.4-58.2)* ref  
             
Facility Type             
Private 48.7 (47.6-49.9) ref  50.3 (45.2-55.4) ref  43.4 (40.7-46.2)* ref  49.2 (48.0-50.4) ref  
Public 38.5 (36.5-40.5)† 0.85 (0.80-0.90) 0.00 27.5 (23.1-32.3)† 0.74 (0.61-0.89) 0.00 28.0 (24.5-31.8)† 0.77 (0.67-0.89) 0.00 41.1 (38.7-43.5)*† 0.87 (0.82-0.93) 0.00 
Hospital 53.7 (50.8-56.6)† 1.05 (0.99-1.12) 0.08 48.4 (37.0-60.0) 1.03 (0.80-1.31) 0.83 47.4 (39.5-55.4) 1.05 (0.90-1.22) 0.58 54.6 (51.4-57.7)† 1.06 (1.00-1.13) 0.07 
Mixed 51.1 (49.1-53.1)† 1.06 (1.01-1.11) 0.02 49.0 (42.9-55.0) 1.03 (0.85-1.24) 0.77 43.7 (39.5-48.0) 1.03 (0.90-1.17) 0.70 52.2 (50.0-54.4)† 1.07 (1.01-1.12) 0.02 
Other 42.1 (37.3-47.2)† 0.92 (0.83-1.02) 0.11 31.0 (15.9-51.7) 0.50 (0.20-1.22) 0.07 36.3 (26.7-47.1) 0.87 (0.66-1.16) 0.33 43.0 (37.6-48.5)† 0.94 (0.84-1.04) 0.22 
             
MSA             
Urban area 50.7 (49.2-52.1)† 1.09 (1.04-1.14) 0.00 49.9 (43.4-56.4)† 1.17 (0.98-1.40) 0.08 45.6 (42.4-48.8)† 1.12 (0.99-1.28) 0.07 51.2 (49.6-52.7)† 1.07 (1.02-1.13) 0.01 
Suburban area  47.1 (45.8-48.4)† 1.06 (1.01-1.11) 0.02 42.4 (37.3-47.6)† 1.13 (0.97-1.31) 0.12 38.5 (35.6-41.4) 0.97 (0.86-1.11) 0.69 48.2 (46.8-49.7)† 1.06 (1.00-1.11) 0.03 
Rural area 40.3 (38.8-41.9) ref  35.2 (31.1-39.5) ref  34.4 (30.7-38.4) ref  41.9 (40.0-43.8) ref  
* p-value < 0.05 compared with DRA Counties; † p-value < 0.05 compared with reference level; NA= Not Applicable 
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Table 3. Unadjusted and Adjusted (Multivariate) logistic regression analysis for 2+ HPV vaccination coverage estimates among adolescent females aged 13-17 years by age at interview for 
selected sociodemographic characteristics, National Immunization Survey-Teen, United States, 2008 - 2012 
Sociodemographic 
Characteristics 
United States 
Delta Regional Authority States (DRA) 
Rest of US 
DRA Counties Non-DRA Counties 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)        
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)   
 % (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
             
Total 38.4 (37.6-39.2)   31.6 (28.8-34.4)   31.7 (30.0-33.6)   39.4 (38.5-40.3)*   
Year             
2008 28.3 (26.4-30.3)† 0.75 (0.70-0.81) 0.00 18.3 (13.7-24.1)† 0.71 (0.52-0.96) 0.02 21.5 (18.1-25.2)† 0.74 (0.61-0.90) 0.00 29.5 (27.3-31.7)*† 0.75 (0.70-0.82) 0.00 
2009 35.9 (34.1-37.6)† 0.89 (0.83-0.95) 0.00 30.4 (24.4-37.2) 0.86 (0.66-1.11) 0.25 28.8 (25.4-32.6)† 0.88 (0.75-1.04) 0.15 36.9 (34.9-38.8)† 0.89 (0.83-0.95) 0.00 
2010 40.7 (38.9-42.5)† 1.03 (0.97-1.09) 0.40 32.5 (27.1-38.3) 1.04 (0.82-1.32) 0.74 32.5 (29.0-36.3) 1.03 (0.88-1.20) 0.70 41.9 (40.0-43.9)* 1.03 (0.96-1.09) 0.46 
2011 43.9 (42.3-45.6) 1.06 (1.00-1.12) 0.05 40.0 (33.4-46.9) 1.14 (0.89-1.47) 0.30 39.8 (35.5-44.3) 1.13 (0.97-1.32) 0.13 44.6 (42.7-46.4) 1.05 (0.99-1.11) 0.13 
2012 43.4 (41.5-45.2) ref  37.3 (30.6-44.6) ref  36.2 (31.9-40.9) ref  44.4 (42.4-46.5) ref  
             
Age of Teen (years)             
13 30.3 (28.7-32.0)† 0.69 (0.65-0.74) 0.00 28.2 (22.7-34.4) 0.82 (0.62-1.09) 0.17 24.1 (20.6-27.9)† 0.70 (0.58-0.84) 0.00 31.2 (29.4-33.0)† 0.69 (0.64-0.74) 0.00 
14 33.9 (32.3-35.7)† 0.78 (0.73-0.83) 0.00 25.8 (20.8-31.6) 0.79 (0.60-1.03) 0.08 29.2 (25.3-33.4)† 0.79 (0.66-0.93) 0.01 34.8 (32.9-36.7)*† 0.78 (0.73-0.84) 0.00 
15 40.7 (38.8-42.5)† 0.91 (0.86-0.96) 0.00 42.0 (35.5-48.8)† 1.26 (1.00-1.58) 0.04 33.5 (29.8-37.5)* 0.95 (0.82-1.11) 0.54 41.5 (39.4-43.6)† 0.90 (0.84-0.96) 0.00 
16 42.3 (40.5-44.1) 0.95 (0.90-1.01) 0.10 31.6 (25.6-38.2) 1.02 (0.81-1.30) 0.85 36.6 (32.5-40.9) 1.02 (0.89-1.19) 0.74 43.3 (41.3-45.4)* 0.95 (0.89-1.01) 0.07 
17 44.7 (42.7-46.7) ref  31.0 (24.8-38.0) ref  35.3 (31.1-39.8) ref  46.2 (44.0-48.4)* ref  
             
Race / ethnicity             
White, non-Hispanic 37.2 (36.3-38.1) ref  30.5 (27.1-34.0) ref  31.3 (29.3-33.3) ref  38.2 (37.2-39.2)* ref  
Black, non-Hispanic 35.7 (33.3-38.0) 0.94 (0.87-1.01) 0.09 31.7 (27.0-36.8) 0.86 (0.69-1.07) 0.18 30.4 (25.7-35.5) 0.93 (0.77-1.12) 0.44 36.9 (34.1-39.7) 0.94 (0.87-1.02) 0.15 
Hispanic 43.2 (40.8-45.5)† 1.20 (1.12-1.27) 0.00 44.4 (28.4-61.6) 1.21 (0.83-1.77) 0.35 37.7 (31.0-44.9) 1.19 (0.98-1.44) 0.09 43.5 (41.0-46.0)† 1.19 (1.11-1.27) 0.00 
Other 40.9 (37.8-44.1)† 1.11 (1.03-1.20) 0.01 33.6 (21.8-47.8) 0.98 (0.68-1.42) 0.92 30.2 (23.2-38.1) 0.93 (0.74-1.17) 0.52 41.8 (38.5-45.3)† 1.12 (1.03-1.21) 0.01 
             
Mother's Education             
<High school 41.2 (38.6-43.9) ref  34.4 (26.6-43.1) ref  30.9 (25.5-36.9) ref  42.5 (39.6-45.5) ref  
High school graduates 36.6 (34.9-38.4)† 0.88 (0.81-0.95) 0.00 31.4 (26.4-36.8) 0.86 (0.65-1.13) 0.29 30.8 (27.2-34.7) 0.96 (0.78-1.20) 0.75 37.6 (35.6-39.6)*† 0.87 (0.80-0.95) 0.00 
> High school graduate, some college 36.9 (35.5-38.4)† 0.87 (0.80-0.94) 0.00 30.5 (25.2-36.3) 0.86 (0.66-1.13) 0.30 29.5 (26.4-32.8) 0.93 (0.75-1.14) 0.49 38.1 (36.5-39.7)*† 0.86 (0.79-0.94) 0.00 
College graduate 39.8 (38.6-41.0) 0.87 (0.80-0.95) 0.00 31.4 (27.3-35.9) 0.85 (0.64-1.14) 0.29 34.7 (31.8-37.7) 1.04 (0.83-1.29) 0.75 40.5 (39.2-41.9)* 0.86 (0.79-0.94) 0.00 
             
Mother's marital status             
Married 37.6 (36.7-38.6) ref  28.8 (25.7-32.0) ref  31.4 (29.4-33.5) ref  38.6 (37.5-39.6)* ref  
Divorced / Widowed / Separated 39.1 (37.3-41.1) 0.99 (0.94-1.05) 0.81 32.3 (26.8-38.4) 1.07 (0.86-1.33) 0.53 31.4 (27.3-35.8) 0.95 (0.81-1.11) 0.54 40.5 (38.3-42.6)* 1.00 (0.94-1.06) 0.99 
Never Married 42.4 (39.4-45.5)† 1.06 (0.97-1.15) 0.22 40.8 (32.2-50.0)† 1.21 (0.91-1.61) 0.20 36.9 (30.0-44.5) 1.22 (0.99-1.50) 0.08 43.1 (39.7-46.6)† 1.04 (0.94-1.14) 0.48 
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Table 3. Unadjusted and Adjusted (Multivariate) logistic regression analysis for 2+ HPV vaccination coverage estimates among adolescent females aged 13-17 years by age at interview for 
selected sociodemographic characteristics, National Immunization Survey-Teen, United States, 2008 - 2012 
Sociodemographic 
Characteristics 
United States 
Delta Regional Authority States (DRA) 
Rest of US 
DRA Counties Non-DRA Counties 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)        
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)   
 % (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
             
Mother's Age (years)             
≤34 years 37.3 (34.5-40.3) ref  40.0 (31.9-48.7) ref  29.4 (23.7-35.8) ref  38.4 (35.0-41.8) ref  
35–44 years 37.1 (35.8-38.4) 1.02 (0.93-1.11) 0.69 28.0 (24.3-32.0)† 0.71 (0.55-0.90) 0.01 31.2 (28.5-33.9) 1.09 (0.88-1.35) 0.45 38.2 (36.8-39.6)* 1.02 (0.93-1.13) 0.62 
≥45 years 39.9 (38.8-41.1) 1.04 (0.95-1.13) 0.43 32.5 (28.4-36.8) 0.82 (0.63-1.05) 0.12 33.0 (30.5-35.7) 1.11 (0.89-1.39) 0.34 40.9 (39.6-42.1)* 1.04 (0.94-1.15) 0.45 
             
Teen had a preventive care visit at age 11 
or 12  years             
Yes visit 40.2 (39.3-41.0) ref  34.7 (31.5-38.0) ref  33.2 (31.3-35.2) ref  41.1 (40.2-42.1)* ref  
No visit 28.5 (26.2-30.9)† 0.89 (0.82-0.96) 0.00 19.3 (14.7-25.0)† 0.73 (0.56-0.95) 0.01 22.0 (18.1-26.6)† 0.96 (0.80-1.15) 0.66 29.7 (27.1-32.5)† 0.89 (0.82-0.96) 0.00 
             
Income to poverty ratio             
<133% 42.1 (40.3-43.9) 1.00 (0.92-1.08) 0.96 37.9 (32.7-43.3) 0.89 (0.67-1.18) 0.43 34.2 (30.3-38.2) 1.03 (0.84-1.25) 0.78 43.2 (41.2-45.3) 1.00 (0.92-1.09) 0.99 
133% - <322% 32.8 (31.4-34.1)† 0.83 (0.79-0.88) 0.00 23.0 (18.9-27.6)† 0.75 (0.59-0.96) 0.03 26.8 (24.0-29.8)† 0.87 (0.75-1.01) 0.08 33.9 (32.4-35.4)*† 0.83 (0.78-0.89) 0.00 
322% - <503% 37.1 (35.5-38.6)† 0.92 (0.87-0.97) 0.00 30.0 (25.0-35.5) 0.84 (0.68-1.05) 0.13 30.7 (27.4-34.3)† 0.90 (0.78-1.04) 0.14 38.1 (36.3-39.8)*† 0.93 (0.87-0.98) 0.01 
>503% 42.9 (41.2-44.6) ref  35.3 (29.4-41.6) ref  38.4 (34.5-42.5) ref  43.5 (41.6-45.3)* ref  
             
Vaccination payment source             
Private Only 37.0 (36.0-38.0) ref  25.7 (22.3-29.3) ref  31.1 (28.9-33.3)* ref  38.0 (36.9-39.1)* ref  
Medicaid / CHIPS  43.8 (42.2-45.5)† 1.17 (1.10-1.24) 0.00 39.6 (34.9-44.5)† 1.51 (1.18-1.94) 0.00 35.4 (31.8-39.1) 1.20 (1.02-1.41) 0.03 45.1 (43.2-47.0)*† 1.16 (1.08-1.24) 0.00 
Uninsured 24.4 (21.5-27.6)† 0.87 (0.76-0.99) 0.03 18.1 (10.9-28.5) 0.98 (0.62-1.54) 0.93 14.7 (9.5-22.0)† 0.82 (0.56-1.21) 0.29 25.3 (22.1-28.8)† 0.86 (0.74-0.99) 0.03 
Military 37.3 (31.9-43.0) 1.01 (0.89-1.16) 0.83 25.9 (11.7-48.2) 1.23 (0.62-2.43) 0.58 26.2 (16.6-38.8) 1.03 (0.73-1.44) 0.89 38.8 (32.9-45.1) 1.01 (0.87-1.16) 0.93 
Other / IHS / AIAN(All) 37.3 (33.9-40.8) 1.00 (0.91-1.11) 0.97 26.8 (17.4-38.8) 0.76 (0.48-1.20) 0.22 31.2 (23.9-39.6) 1.01 (0.80-1.27) 0.95 38.2 (34.5-42.1) 1.00 (0.90-1.11) 0.98 
             
Received provider recommendation for 
HPV vaccination             
Yes 51.2 (50.1-52.3) ref  47.4 (43.2-51.7) ref  46.1 (43.5-48.8) ref  51.8 (50.6-53.0) ref  
No 21.7 (20.6-22.9)† 0.46 (0.44-0.49) 0.00 18.0 (14.9-21.7)† 0.45 (0.37-0.55) 0.00 15.0 (13.1-17.1)† 0.36 (0.31-0.42) 0.00 22.7 (21.5-24.1)*† 0.48 (0.45-0.50) 0.00 
             
Do you know about HPV Vaccine  NA   NA   NA   NA  
Yes 38.7 (37.8-39.7)   30.8 (27.8-34.1)   32.3 (30.2-34.4)   39.8 (38.7-40.8)*   
No 22.3 (19.0-25.9)†   24.8 (16.2-36.0)   14.9 (10.1-21.4)†   23.0 (19.3-27.2)†   
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Table 3. Unadjusted and Adjusted (Multivariate) logistic regression analysis for 2+ HPV vaccination coverage estimates among adolescent females aged 13-17 years by age at interview for 
selected sociodemographic characteristics, National Immunization Survey-Teen, United States, 2008 - 2012 
Sociodemographic 
Characteristics 
United States 
Delta Regional Authority States (DRA) 
Rest of US 
DRA Counties Non-DRA Counties 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)        
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)   
 % (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Have you heard about HPV vaccine  NA   NA   NA   NA  
Yes 38.5 (37.5-39.5)   31.0 (27.7-34.5)   32.2 (30.1-34.4)   39.5 (38.4-40.5)   
No 30.5 (27.9-33.3)†   26.1 (20.3-32.8)   23.2 (18.9-28.2)†   31.6 (28.7-34.8)†   
             
Number of Total Providers             
1 39.4 (38.2-40.5) ref  32.2 (28.2-36.5) ref  31.6 (29.1-34.3) ref  40.4 (39.2-41.7)* ref  
2 - 3 36.9 (35.4-38.4)† 0.90 (0.86-0.95) 0.00 29.5 (25.2-34.2) 0.87 (0.71-1.05) 0.15 31.9 (28.8-35.2) 1.00 (0.88-1.13) 0.97 37.8 (36.2-39.5)*† 0.89 (0.85-0.94) 0.00 
4 or more 38.1 (36.2-40.1) 0.86 (0.80-0.92) 0.00 34.5 (28.0-41.5) 0.85 (0.66-1.09) 0.20 31.7 (27.6-36.1) 0.88 (0.74-1.04) 0.12 39.0 (36.8-41.2) 0.86 (0.80-0.92) 0.00 
             
Physician contacts within past year             
None  26.9 (25.1-28.9)† 0.73 (0.67-0.79) 0.00 23.4 (17.5-30.5)† 0.87 (0.66-1.15) 0.32 22.1 (18.1-26.7)† 0.73 (0.59-0.90) 0.00 27.6 (25.5-29.7)† 0.72 (0.66-0.78) 0.00 
1 35.1 (33.6-36.7)† 0.81 (0.77-0.86) 0.00 31.5 (26.1-37.6) 0.99 (0.79-1.24) 0.95 28.7 (25.5-32.2)† 0.93 (0.81-1.08) 0.33 36.0 (34.3-37.7)† 0.80 (0.75-0.85) 0.00 
2 - 3 41.0 (39.6-42.4)† 0.91 (0.86-0.95) 0.00 30.8 (26.4-35.7) 0.85 (0.70-1.03) 0.09 34.6 (31.5-37.8) 0.98 (0.86-1.12) 0.80 42.1 (40.5-43.7)*† 0.90 (0.85-0.95) 0.00 
4 or more 46.6 (44.9-48.3) ref  38.1 (32.4-44.2) ref  36.4 (32.7-40.2) ref  48.3 (46.3-50.2)* ref  
             
Facility Type             
Private 40.8 (39.7-41.9) ref  39.2 (34.3-44.4) ref  36.2 (33.5-38.9) ref  41.2 (40.0-42.5) ref  
Public 27.5 (25.7-29.3)† 0.76 (0.70-0.81) 0.00 19.4 (15.6-23.8)† 0.68 (0.53-0.87) 0.00 19.4 (16.3-22.9)† 0.66 (0.55-0.79) 0.00 29.5 (27.4-31.6)*† 0.78 (0.72-0.85) 0.00 
Hospital 44.0 (41.1-46.9)† 1.05 (0.98-1.13) 0.17 40.8 (30.1-52.4) 1.16 (0.88-1.54) 0.30 40.9 (33.3-49.0) 1.14 (0.96-1.35) 0.15 44.4 (41.3-47.6) 1.04 (0.97-1.13) 0.28 
Mixed 41.1 (39.1-43.1) 1.03 (0.97-1.10) 0.27 39.9 (34.0-46.2) 1.17 (0.93-1.46) 0.18 33.4 (29.6-37.5) 0.96 (0.82-1.12) 0.63 42.2 (40.0-44.4) 1.04 (0.98-1.11) 0.21 
Other 32.4 (28.2-37.0)† 0.88 (0.78-1.00) 0.03 18.1 (8.1-35.6)† 0.51 (0.19-1.40) 0.14 23.8 (16.5-33.1)† 0.73 (0.51-1.04) 0.06 33.7 (28.9-38.8)*† 0.91 (0.80-1.03) 0.12 
             
MSA             
Urban area 40.4 (39.1-41.8)† 1.04 (0.99-1.10) 0.14 36.7 (30.8-43.1)† 1.10 (0.88-1.38) 0.38 35.8 (32.8-39.0)† 1.02 (0.87-1.19) 0.83 41.0 (39.5-42.5)† 1.03 (0.97-1.09) 0.34 
Suburban area  38.7 (37.4-39.9)† 1.02 (0.96-1.07) 0.53 34.9 (30.1-40.0)† 1.19 (0.98-1.43) 0.07 30.8 (28.1-33.6) 0.92 (0.79-1.06) 0.26 39.7 (38.3-41.1)† 1.01 (0.96-1.08) 0.63 
Rural area 32.7 (31.2-34.2) ref  26.9 (23.1-31.0) ref  27.4 (23.9-31.2) ref  34.2 (32.5-36.0)* ref  
* p-value < 0.05 compared with DRA Counties; † p-value < 0.05 compared with reference level; NA= Not Applicable 
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Table 4. Unadjusted and Adjusted (Multivariate) logistic regression analysis for 3+ HPV vaccination coverage estimates among adolescent females aged 13-17 years by age at interview for 
selected sociodemographic characteristics, National Immunization Survey-Teen, United States, 2008 - 2012 
Sociodemographic 
Characteristics 
United States 
Delta Regional Authority States (DRA) 
Rest of US 
DRA Counties Non-DRA Counties 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)        
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)   
 % (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
             
Total 28.9 (28.2-29.7)*   22.5 (20.1-25.0)   24.0 (22.4-25.7)   29.7 (28.9-30.6)*   
Year             
2008 17.9 (16.3-19.6)† 0.60 (0.55-0.66) 0.00 9.5 (6.8-13.2)† 0.46 (0.30-0.69) 0.00 13.5 (10.8-16.7)† 0.62 (0.49-0.80) 0.00 18.7 (16.9-20.6)*† 0.60 (0.54-0.67) 0.00 
2009 26.7 (25.2-28.3)† 0.85 (0.79-0.92) 0.00 20.2 (15.3-26.4) 0.71 (0.50-1.01) 0.06 22.2 (19.0-25.7) 0.91 (0.74-1.12) 0.38 27.5 (25.8-29.2)*† 0.85 (0.78-0.92) 0.00 
2010 32.0 (30.4-33.6) 1.04 (0.96-1.12) 0.33 27.1 (22.1-32.7) 1.10 (0.83-1.47) 0.50 26.6 (23.4-30.2) 1.13 (0.94-1.35) 0.20 32.8 (31.0-34.7) 1.03 (0.95-1.11) 0.51 
2011 34.8 (33.2-36.5) 1.08 (1.00-1.15) 0.04 27.7 (22.1-34.2) 1.01 (0.74-1.38) 0.94 30.8 (26.6-35.2) 1.18 (0.98-1.43) 0.08 35.5 (33.8-37.3)* 1.07 (0.99-1.15) 0.09 
2012 33.5 (31.7-35.2) ref  28.2 (22.2-35.1) ref  27.1 (23.3-31.2) ref  34.4 (32.5-36.4) ref  
             
Age of Teen (years)             
13 20.1 (18.8-21.5)† 0.58 (0.53-0.63) 0.00 18.6 (14.2-24.1) 0.72 (0.49-1.05) 0.09 16.5 (13.7-19.7)† 0.59 (0.47-0.75) 0.00 20.6 (19.1-22.1)† 0.57 (0.52-0.63) 0.00 
14 25.6 (24.1-27.2)† 0.74 (0.69-0.80) 0.00 17.1 (13.0-22.1) 0.69 (0.49-0.98) 0.04 22.4 (18.9-26.4)† 0.76 (0.62-0.93) 0.01 26.2 (24.6-28.0)*† 0.74 (0.68-0.81) 0.00 
15 29.8 (28.1-31.4)† 0.83 (0.78-0.90) 0.00 29.7 (24.1-36.0) 1.14 (0.85-1.53) 0.37 24.2 (20.9-27.8) 0.86 (0.72-1.04) 0.13 30.4 (28.6-32.3)† 0.83 (0.76-0.89) 0.00 
16 33.7 (32.0-35.4) 0.95 (0.89-1.02) 0.16 22.9 (18.0-28.7) 1.00 (0.72-1.37) 0.98 28.6 (24.8-32.7) 0.99 (0.83-1.18) 0.91 34.7 (32.8-36.6)* 0.95 (0.88-1.02) 0.16 
17 35.4 (33.5-37.4) ref  24.9 (19.1-31.7) ref  28.6 (24.6-32.9) ref  36.6 (34.5-38.8)* ref  
             
Race / ethnicity             
White, non-Hispanic 29.4 (28.6-30.2) ref  22.6 (19.8-25.8) ref  24.4 (22.6-26.3) ref  30.3 (29.3-31.2)* ref  
Black, non-Hispanic 25.6 (23.5-27.9)† 0.88 (0.80-0.97) 0.01 21.6 (17.6-26.2) 0.92 (0.69-1.22) 0.57 21.0 (17.0-25.8) 0.85 (0.67-1.08) 0.18 26.8 (24.2-29.5)† 0.88 (0.79-0.98) 0.01 
Hispanic 29.7 (27.7-31.8) 1.10 (1.02-1.19) 0.02 28.6 (16.5-44.8) 1.07 (0.64-1.81) 0.79 27.1 (21.0-34.3) 1.07 (0.84-1.37) 0.59 29.9 (27.7-32.1) 1.09 (1.00-1.18) 0.05 
Other 29.9 (27.1-32.8) 1.05 (0.95-1.16) 0.33 23.6 (14.0-37.1) 0.98 (0.58-1.65) 0.93 21.7 (16.3-28.4) 0.82 (0.62-1.11) 0.18 30.6 (27.6-33.8) 1.06 (0.95-1.17) 0.29 
             
Mother's Education             
<High school 28.0 (25.8-30.4) ref  20.7 (14.8-28.2) ref  23.4 (18.5-29.2) ref  28.8 (26.3-31.4)* ref  
High school graduates 26.3 (24.7-27.9) 0.85 (0.77-0.94) 0.00 22.8 (18.5-27.7) 0.95 (0.64-1.42) 0.82 20.9 (17.9-24.3) 0.77 (0.59-0.99) 0.04 27.1 (25.4-29.0) 0.86 (0.77-0.96) 0.01 
> High school graduate, some college 28.1 (26.8-29.4) 0.89 (0.81-0.97) 0.01 21.8 (17.3-27.1) 0.95 (0.64-1.41) 0.79 23.5 (20.6-26.6) 0.87 (0.68-1.10) 0.26 28.9 (27.4-30.4)* 0.89 (0.80-0.98) 0.02 
College graduate 32.0 (30.8-33.1)† 0.91 (0.83-1.01) 0.08 23.7 (20.0-27.8) 0.97 (0.65-1.45) 0.87 27.3 (24.6-30.1) 0.89 (0.68-1.15) 0.37 32.7 (31.5-34.0)*† 0.92 (0.82-1.02) 0.11 
             
Mother's marital status             
Married 28.8 (27.9-29.6) ref  21.1 (18.5-23.9) ref  23.9 (22.1-25.7) ref  29.6 (28.6-30.5)* ref  
Divorced / Widowed / Separated 28.9 (27.3-30.7) 0.97 (0.91-1.04) 0.44 22.2 (17.7-27.6) 1.09 (0.82-1.46) 0.56 24.1 (20.3-28.3) 0.99 (0.82-1.19) 0.90 29.9 (28.0-31.8)* 0.98 (0.91-1.05) 0.52 
Never Married 29.3 (26.7-32.1) 1.00 (0.90-1.12) 0.94 28.1 (20.6-37.1) 1.31 (0.92-1.88) 0.15 25.8 (19.5-33.4) 1.26 (0.97-1.64) 0.09 29.8 (26.8-32.9) 0.97 (0.86-1.10) 0.66 
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Table 4. Unadjusted and Adjusted (Multivariate) logistic regression analysis for 3+ HPV vaccination coverage estimates among adolescent females aged 13-17 years by age at interview for 
selected sociodemographic characteristics, National Immunization Survey-Teen, United States, 2008 - 2012 
Sociodemographic 
Characteristics 
United States 
Delta Regional Authority States (DRA) 
Rest of US 
DRA Counties Non-DRA Counties 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)        
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)   
 % (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
             
Mother's Age (years)             
≤34 years 25.1 (22.5-27.8) ref  23.9 (17.6-31.6) ref  17.4 (12.9-23.2) ref  26.3 (23.4-29.5) ref  
35–44 years 27.7 (26.5-28.8) 1.08 (0.97-1.21) 0.16 20.6 (17.4-24.3) 0.81 (0.57-1.14) 0.24 23.5 (21.1-26.0)† 1.38 (1.02-1.86) 0.03 28.5 (27.2-29.8)* 1.07 (0.94-1.20) 0.30 
≥45 years 31.0 (30.0-32.0)† 1.09 (0.97-1.22) 0.13 24.3 (20.7-28.4) 0.97 (0.68-1.39) 0.89 26.4 (24.1-28.9)† 1.44 (1.05-1.96) 0.02 31.7 (30.5-32.8)*† 1.06 (0.94-1.20) 0.34 
             
Teen had a preventive care visit at age 11 
or 12  years             
Yes visit 30.6 (29.8-31.4) ref  24.5 (21.8-27.4) ref  25.5 (23.8-27.4) ref  31.4 (30.5-32.3)* ref  
No visit 19.2 (17.3-21.3)† 0.80 (0.73-0.88) 0.00 14.6 (10.5-19.8) 0.80 (0.58-1.09) 0.15 13.6 (10.5-17.5)† 0.81 (0.63-1.03) 0.08 20.1 (17.9-22.5)*† 0.80 (0.72-0.89) 0.00 
             
Income to poverty ratio             
<133% 29.3 (27.7-31.0)† 0.95 (0.87-1.05) 0.33 24.6 (20.3-29.6) 0.74 (0.51-1.06) 0.11 23.9 (20.5-27.7)† 1.05 (0.82-1.34) 0.70 30.2 (28.4-32.0)*† 0.95 (0.86-1.06) 0.37 
133% - <322% 24.9 (23.7-26.2)† 0.83 (0.77-0.89) 0.00 17.2 (13.7-21.3)† 0.76 (0.56-1.02) 0.07 20.4 (17.9-23.1)† 0.90 (0.75-1.09) 0.28 25.8 (24.5-27.2)*† 0.83 (0.77-0.89) 0.00 
322% - <503% 29.1 (27.7-30.6)† 0.91 (0.85-0.98) 0.01 25.0 (20.3-30.4) 0.96 (0.73-1.25) 0.74 24.5 (21.5-27.8)† 0.93 (0.78-1.10) 0.39 29.8 (28.2-31.5)† 0.91 (0.85-0.98) 0.01 
>503% 34.1 (32.6-35.7) ref  25.7 (20.9-31.3) ref  30.3 (26.7-34.2) ref  34.7 (33.0-36.4)* ref  
             
Vaccination payment source             
Private Only 29.1 (28.2-30.0) ref  19.3 (16.5-22.5) ref  24.4 (22.4-26.5)* ref  29.9 (28.9-30.9)* ref  
Medicaid / CHIPS  31.4 (29.9-32.9)† 1.16 (1.08-1.25) 0.00 27.5 (23.4-32.0)† 1.64 (1.21-2.22) 0.00 25.1 (22.0-28.5) 1.18 (0.98-1.42) 0.09 32.4 (30.7-34.2)*† 1.15 (1.06-1.25) 0.00 
Uninsured 16.5 (14.1-19.3)† 0.80 (0.68-0.95) 0.01 10.7 (5.4-20.2) 1.00 (0.55-1.81) 1.00 8.9 (5.0-15.5)† 0.76 (0.46-1.26) 0.26 17.2 (14.6-20.3)† 0.79 (0.66-0.95) 0.01 
Military 27.8 (22.8-33.5) 0.94 (0.79-1.12) 0.52 21.9 (8.9-44.7) 1.32 (0.57-3.04) 0.54 15.9 (8.7-27.2) 0.85 (0.55-1.33) 0.47 29.2 (23.7-35.5) 0.94 (0.78-1.13) 0.52 
Other / IHS / AIAN(All) 27.7 (24.8-30.9) 0.98 (0.87-1.10) 0.75 17.5 (10.3-28.2) 0.64 (0.35-1.16) 0.12 28.3 (21.1-36.7) 1.23 (0.95-1.60) 0.13 27.9 (24.7-31.5)* 0.96 (0.84-1.09) 0.50 
             
Received provider recommendation for 
HPV vaccination             
Yes 39.2 (38.2-40.3) ref  34.0 (30.1-38.1) ref  35.5 (33.0-38.1) ref  39.8 (38.6-40.9)* ref  
No 15.6 (14.7-16.6)† 0.46 (0.43-0.49) 0.00 12.5 (10.0-15.6)† 0.46 (0.36-0.59) 0.00 10.8 (9.2-12.6)† 0.35 (0.29-0.42) 0.00 16.4 (15.3-17.5)*† 0.47 (0.44-0.51) 0.00 
             
Do you know about HPV Vaccine  NA   NA   NA   NA  
Yes 29.3 (28.4-30.1)   21.8 (19.1-24.6)   24.7 (22.8-26.7)   30.1 (29.1-31.0)*   
No 14.4 (11.8-17.4)†   16.2 (9.8-25.6)   8.3 (5.3-13.0)†   15.0 (12.1-18.4)†   
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Table 4. Unadjusted and Adjusted (Multivariate) logistic regression analysis for 3+ HPV vaccination coverage estimates among adolescent females aged 13-17 years by age at interview for 
selected sociodemographic characteristics, National Immunization Survey-Teen, United States, 2008 - 2012 
Sociodemographic 
Characteristics 
United States 
Delta Regional Authority States (DRA) 
Rest of US 
DRA Counties Non-DRA Counties 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)        
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)   
 % (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Have you heard about HPV vaccine  NA   NA   NA   NA  
Yes 29.3 (28.4-30.1)   22.0 (19.1-25.1)   24.7 (22.7-26.8)   30.0 (29.1-31.0)   
No 20.9 (18.6-23.5)†   18.6 (13.8-24.5)   17.1 (13.4-21.7)†   21.5 (18.9-24.4)†   
             
Number of Total Providers             
1 29.9 (28.9-30.9) ref  22.6 (19.2-26.5) ref  24.7 (22.4-27.1) ref  30.7 (29.5-31.8)* ref  
2 - 3 27.7 (26.4-29.1)† 0.88 (0.83-0.94) 0.00 20.7 (17.1-24.8) 0.93 (0.72-1.20) 0.58 22.7 (19.9-25.7) 0.89 (0.76-1.04) 0.14 28.7 (27.2-30.3)*† 0.88 (0.83-0.94) 0.00 
4 or more 28.1 (26.4-29.9) 0.83 (0.77-0.91) 0.00 26.0 (20.2-32.6) 0.99 (0.73-1.35) 0.95 24.3 (20.7-28.3) 0.86 (0.71-1.05) 0.14 28.6 (26.7-30.6) 0.83 (0.76-0.91) 0.00 
             
Physician contacts within past year             
None  21.1 (19.4-22.9)† 0.74 (0.68-0.81) 0.00 17.5 (12.4-24.1)† 0.92 (0.65-1.30) 0.63 15.4 (12.2-19.2)† 0.67 (0.52-0.87) 0.00 21.8 (19.9-23.8)† 0.74 (0.67-0.81) 0.00 
1 25.9 (24.6-27.3)† 0.75 (0.70-0.80) 0.00 21.7 (17.2-27.0) 0.97 (0.73-1.29) 0.85 21.1 (18.2-24.3)† 0.85 (0.71-1.01) 0.06 26.5 (25.1-28.1)† 0.73 (0.68-0.79) 0.00 
2 - 3 29.9 (28.6-31.2)† 0.83 (0.78-0.88) 0.00 21.8 (18.1-26.1) 0.84 (0.65-1.09) 0.19 26.1 (23.3-29.2) 0.92 (0.78-1.07) 0.28 30.6 (29.2-32.1)*† 0.81 (0.76-0.87) 0.00 
4 or more 37.2 (35.6-38.9) ref  27.1 (22.1-32.7) ref  29.2 (25.8-32.8) ref  38.7 (36.9-40.6)* ref  
             
Facility Type             
Private 31.3 (30.3-32.4) ref  30.9 (26.4-35.7) ref  28.5 (26.1-31.1) ref  31.6 (30.5-32.7) ref  
Public 19.0 (17.5-20.6)† 0.71 (0.65-0.78) 0.00 12.5 (9.5-16.2)† 0.52 (0.38-0.72) 0.00 12.0 (9.4-15.1)† 0.55 (0.43-0.70) 0.00 20.7 (18.9-22.6)*† 0.75 (0.68-0.83) 0.00 
Hospital 32.9 (30.2-35.7) 1.04 (0.95-1.14) 0.39 24.7 (16.8-34.7) 0.92 (0.63-1.34) 0.65 33.8 (26.5-42.0) 1.20 (0.97-1.47) 0.10 33.0 (30.1-36.1) 1.03 (0.93-1.13) 0.57 
Mixed 30.9 (29.1-32.8) 1.02 (0.94-1.09) 0.69 27.2 (22.0-33.2) 0.91 (0.69-1.21) 0.51 24.7 (21.5-28.3) 0.95 (0.78-1.15) 0.58 31.9 (29.9-34.1) 1.03 (0.95-1.12) 0.48 
Other 23.9 (20.1-28.1)† 0.89 (0.76-1.04) 0.13 13.8 (5.3-31.4)† 0.55 (0.19-1.58) 0.23 16.0 (10.1-24.4)† 0.64 (0.41-1.00) 0.04 24.9 (20.8-29.6)† 0.92 (0.79-1.09) 0.33 
             
MSA             
Urban area 30.0 (28.8-31.3)† 1.03 (0.97-1.11) 0.34 21.7 (17.4-26.7) 0.83 (0.61-1.13) 0.23 27.4 (24.5-30.5)*† 1.13 (0.93-1.38) 0.21 30.5 (29.1-31.9)*† 1.01 (0.94-1.09) 0.77 
Suburban area  29.5 (28.4-30.6)† 1.00 (0.94-1.07) 0.98 27.7 (23.5-32.4)† 1.14 (0.91-1.44) 0.25 24.2 (21.8-26.8)† 1.06 (0.87-1.28) 0.57 30.2 (28.9-31.4)† 0.98 (0.91-1.05) 0.58 
Rural area 24.6 (23.3-26.0) ref  19.9 (16.4-23.9) ref  17.9 (15.2-20.9) ref  26.3 (24.7-27.9)* ref  
* p-value < 0.05 compared with DRA Counties; † p-value < 0.05 compared with reference level; NA= Not Applicable 
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Table 5. Unadjusted and Adjusted (Multivariate) logistic regression analysis for 3 dose series completion of HPV vaccination coverage estimates among adolescent females aged 13-17 
years by age at interview for selected sociodemographic characteristics, National Immunization Survey-Teen, United States, 2008 - 2012 
Sociodemographic 
Characteristics 
United States 
Delta Regional Authority States (DRA) 
Rest of US 
DRA Counties Non-DRA Counties 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)        
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)   
 % (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
             
Total 67.4 (66.1-68.6)   60.9 (55.8-65.8)   66.9 (63.7-70.0)   67.6 (66.2-69.0)*   
Year             
2008 59.6 (55.5-63.5)† 0.84 (0.78-0.90) 0.00 43.2 (30.4-57.0)† 0.64 (0.44-0.91) 0.01 58.5 (49.5-67.0) 0.94 (0.79-1.12) 0.51 60.1 (55.6-64.3)*† 0.83 (0.77-0.90) 0.00 
2009 67.5 (64.4-70.5) 0.98 (0.93-1.04) 0.51 58.2 (46.0-69.6) 0.86 (0.66-1.11) 0.23 69.5 (62.9-75.3) 1.08 (0.94-1.25) 0.26 67.6 (64.2-70.9) 0.98 (0.92-1.04) 0.43 
2010 69.6 (66.8-72.2) 1.04 (0.98-1.09) 0.20 68.6 (58.9-77.0) 1.08 (0.88-1.31) 0.46 73.4 (67.4-78.6)† 1.15 (1.02-1.31) 0.02 69.3 (66.2-72.2) 1.02 (0.97-1.08) 0.45 
2011 70.7 (68.4-73.0)† 1.05 (1.00-1.10) 0.04 63.0 (51.6-73.0) 0.96 (0.77-1.20) 0.73 69.4 (62.6-75.5) 1.12 (0.99-1.27) 0.07 71.1 (68.5-73.5) 1.05 (0.99-1.10) 0.09 
2012 66.7 (64.0-69.3) ref  62.7 (52.0-72.3) ref  62.0 (54.3-69.1) ref  67.3 (64.4-70.1) ref  
             
Age of Teen (years)             
13 58.0 (54.9-61.2)† 0.84 (0.78-0.89) 0.00 56.4 (44.9-67.2) 0.90 (0.70-1.15) 0.39 56.9 (48.9-64.5)† 0.81 (0.70-0.93) 0.00 58.2 (54.7-61.6)† 0.84 (0.78-0.90) 0.00 
14 67.1 (64.1-69.9)† 0.97 (0.92-1.02) 0.25 52.8 (41.6-63.7) 0.79 (0.61-1.03) 0.08 70.0 (61.9-76.9)* 1.00 (0.88-1.13) 0.96 67.3 (64.0-70.3)*† 0.97 (0.92-1.03) 0.34 
15 65.1 (62.2-67.9)† 0.92 (0.87-0.97) 0.00 64.0 (52.4-74.2) 0.93 (0.74-1.16) 0.51 63.6 (57.0-69.8)† 0.88 (0.78-1.00) 0.06 65.3 (62.1-68.4)† 0.92 (0.87-0.98) 0.01 
16 71.7 (68.9-74.2) 0.99 (0.94-1.04) 0.77 62.2 (50.7-72.5) 0.94 (0.75-1.18) 0.61 68.7 (61.6-75.0) 0.93 (0.83-1.04) 0.20 72.2 (69.2-75.0) 1.00 (0.95-1.06) 0.98 
17 72.3 (69.5-74.9) ref  68.0 (56.4-77.7) ref  74.8 (67.7-80.7) ref  72.2 (69.2-75.1) ref  
             
Race / ethnicity             
White, non-Hispanic 72.8 (71.4-74.2) ref  66.7 (59.9-72.9) ref  71.3 (67.7-74.6) ref  73.2 (71.6-74.7) ref  
Black, non-Hispanic 60.1 (56.4-63.7)† 0.90 (0.84-0.96) 0.00 54.7 (46.2-62.9)† 0.95 (0.78-1.15) 0.57 56.2 (47.2-64.7)† 0.93 (0.80-1.08) 0.31 61.1 (56.8-65.3)† 0.89 (0.83-0.96) 0.00 
Hispanic 59.6 (56.2-62.9)† 0.94 (0.89-0.99) 0.03 NA NA NA 63.2 (52.3-72.8) 0.96 (0.83-1.12) 0.61 59.4 (55.9-62.9)† 0.94 (0.89-0.99) 0.03 
Other 65.5 (60.6-70.1)† 0.96 (0.89-1.03) 0.25 NA NA NA 61.6 (45.6-75.4) 0.84 (0.64-1.11) 0.16 65.8 (60.6-70.7)† 0.96 (0.89-1.04) 0.32 
             
Mother's Education             
<High school 56.4 (52.5-60.2) ref  48.4 (35.3-61.7) ref  63.4 (53.1-72.6) ref  56.1 (51.9-60.3) ref  
High school graduates 62.8 (59.9-65.7)† 0.99 (0.93-1.07) 0.86 59.8 (50.2-68.6) 1.03 (0.78-1.37) 0.83 57.5 (50.6-64.2) 0.84 (0.73-0.97) 0.02 63.5 (60.2-66.8)† 1.01 (0.94-1.09) 0.81 
> High school graduate, some college 68.2 (65.9-70.3)† 1.04 (0.98-1.12) 0.21 66.1 (55.7-75.1)† 1.20 (0.90-1.60) 0.20 69.3 (63.4-74.6) 0.97 (0.85-1.10) 0.60 68.1 (65.6-70.5)† 1.05 (0.97-1.12) 0.23 
College graduate 75.5 (73.8-77.2)† 1.07 (1.00-1.15) 0.05 65.5 (57.2-72.9)† 1.08 (0.79-1.49) 0.62 74.4 (69.7-78.6) 0.93 (0.81-1.08) 0.35 75.9 (74.0-77.6)*† 1.08 (1.00-1.17) 0.03 
             
Mother's marital status             
Married 70.0 (68.5-71.4) ref  64.3 (58.1-70.1) ref  68.8 (65.0-72.4) ref  70.2 (68.6-71.8) ref  
Divorced / Widowed / Separated 64.3 (61.3-67.2)† 0.95 (0.90-1.00) 0.04 57.3 (47.1-67.0) 0.97 (0.79-1.19) 0.78 65.2 (57.5-72.1) 1.02 (0.91-1.14) 0.77 64.5 (61.1-67.7)† 0.94 (0.89-1.00) 0.04 
Never Married 56.6 (52.2-60.9)† 0.93 (0.87-1.00) 0.05 58.6 (44.8-71.1) 1.10 (0.86-1.39) 0.46 59.0 (47.8-69.3) 1.01 (0.86-1.18) 0.90 56.3 (51.4-61.1)† 0.92 (0.85-0.99) 0.02 
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Table 5. Unadjusted and Adjusted (Multivariate) logistic regression analysis for 3 dose series completion of HPV vaccination coverage estimates among adolescent females aged 13-17 
years by age at interview for selected sociodemographic characteristics, National Immunization Survey-Teen, United States, 2008 - 2012 
Sociodemographic 
Characteristics 
United States 
Delta Regional Authority States (DRA) 
Rest of US 
DRA Counties Non-DRA Counties 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)        
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)   
 % (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
             
Mother's Age (years)             
≤34 years 53.9 (49.4-58.3) ref  55.2 (41.6-68.1) ref  44.9 (34.7-55.6) ref  54.9 (49.8-59.8) ref  
35–44 years 65.7 (63.6-67.7)† 1.12 (1.04-1.21) 0.00 59.4 (52.0-66.4) 1.01 (0.78-1.30) 0.94 66.5 (61.7-71.0)† 1.35 (1.10-1.66) 0.00 65.8 (63.5-68.0)† 1.10 (1.02-1.20) 0.01 
≥45 years 72.1 (70.4-73.8)† 1.14 (1.05-1.23) 0.00 66.2 (58.3-73.3) 1.17 (0.90-1.51) 0.21 74.1 (69.5-78.3)† 1.40 (1.14-1.73) 0.00 72.1 (70.2-73.9)† 1.11 (1.02-1.21) 0.01 
             
Teen had a preventive care visit at age 11 
or 12  years             
Yes visit 68.4 (67.0-69.7) ref  60.8 (55.3-66.1) ref  69.1 (65.7-72.3)* ref  68.5 (67.1-70.0)* ref  
No visit 58.2 (53.5-62.7)† 0.91 (0.84-0.98) 0.00 61.8 (48.4-73.6) 1.01 (0.80-1.28) 0.92 47.2 (37.2-57.5)† 0.81 (0.69-0.96) 0.01 59.1 (54.0-64.1)† 0.92 (0.85-0.99) 0.02 
             
Income to poverty ratio             
<133% 59.4 (56.8-62.0)† 0.95 (0.88-1.02) 0.13 55.2 (47.0-63.2) 0.67 (0.50-0.89) 0.01 58.9 (52.1-65.3)† 0.97 (0.82-1.16) 0.77 59.7 (56.8-62.5)† 0.95 (0.88-1.03) 0.19 
133% - <322% 66.0 (63.5-68.4)† 0.94 (0.89-0.99) 0.02 61.3 (51.1-70.6) 0.85 (0.70-1.04) 0.14 63.7 (57.8-69.2)† 0.93 (0.82-1.06) 0.30 66.3 (63.6-69.0)† 0.94 (0.89-1.00) 0.04 
322% - <503% 73.9 (71.6-76.0) 0.98 (0.94-1.03) 0.52 72.2 (62.6-80.1) 1.01 (0.85-1.20) 0.87 75.8 (70.1-80.7) 1.02 (0.90-1.16) 0.76 73.7 (71.2-76.0) 0.98 (0.93-1.03) 0.41 
>503% 76.0 (73.6-78.2) ref  68.4 (56.8-78.0) ref  77.0 (70.5-82.5) ref  76.1 (73.5-78.4) ref  
             
Vaccination payment source             
Private Only 73.0 (71.4-74.6) ref  64.5 (56.3-72.0) ref  73.1 (69.3-76.5) ref  73.2 (71.4-75.0)* ref  
Medicaid / CHIPS  62.1 (59.7-64.4)† 1.00 (0.94-1.06) 0.95 60.2 (52.8-67.1) 1.28 (1.00-1.63) 0.05 61.2 (55.3-66.8)† 1.05 (0.92-1.19) 0.48 62.2 (59.6-64.8)† 0.99 (0.93-1.05) 0.73 
Uninsured 50.7 (44.4-57.0)† 0.88 (0.78-0.98) 0.01 47.8 (26.4-70.1) 1.10 (0.72-1.68) 0.68 37.8 (21.4-57.6)† 0.82 (0.58-1.15) 0.19 51.4 (44.7-58.1)† 0.88 (0.78-0.99) 0.02 
Military 64.8 (57.0-72.0)† 0.90 (0.79-1.02) 0.08 64.5 (34.1-86.4) 0.93 (0.42-2.07) 0.86 36.0 (18.1-58.8)† 0.70 (0.48-1.03) 0.03 67.9 (59.8-75.0) 0.93 (0.82-1.06) 0.25 
Other / IHS / AIAN(All) 65.1 (59.4-70.4)† 0.99 (0.91-1.07) 0.71 49.2 (29.8-68.8) 0.64 (0.34-1.18) 0.10 79.5 (65.5-88.8)* 1.26 (1.10-1.44) 0.01 64.2 (58.0-69.9)† 0.96 (0.88-1.05) 0.41 
             
Received provider recommendation for 
HPV vaccination             
Yes 70.7 (69.3-72.1) ref  64.2 (58.0-70.0) ref  71.4 (67.8-74.7)* ref  70.8 (69.3-72.3)* ref  
No 58.9 (55.9-61.8)† 0.90 (0.86-0.95) 0.00 54.3 (44.8-63.4) 0.93 (0.78-1.12) 0.44 55.4 (48.7-61.9)† 0.88 (0.78-0.99) 0.02 59.3 (56.1-62.5)† 0.91 (0.86-0.96) 0.00 
             
Do you know about HPV Vaccine  NA   NA   NA   NA  
Yes 69.2 (67.7-70.5)   61.7 (55.7-67.5)   69.7 (66.3-73.0)*   69.3 (67.8-70.8)*   
No 47.2 (38.8-55.7)†   51.8 (31.3-71.7)   44.7 (28.2-62.5)†   47.1 (37.9-56.5)†   
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Table 5. Unadjusted and Adjusted (Multivariate) logistic regression analysis for 3 dose series completion of HPV vaccination coverage estimates among adolescent females aged 13-17 
years by age at interview for selected sociodemographic characteristics, National Immunization Survey-Teen, United States, 2008 - 2012 
Sociodemographic 
Characteristics 
United States 
Delta Regional Authority States (DRA) 
Rest of US 
DRA Counties Non-DRA Counties 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)        
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)       
% (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Weighted 
Proportion 
(Unadjusted)   
 % (95% C.I.) 
Adjusted 
Prevalence 
Ratio (APR)      
% (95% C.I.) 
P-value 
Have you heard about HPV vaccine  NA   NA   NA   NA  
Yes 69.7 (68.3-71.1)   61.3 (54.8-67.5)   70.6 (67.1-73.9)*   69.9 (68.3-71.4)*   
No 56.3 (50.9-61.6)†   61.4 (47.8-73.5)   60.6 (49.8-70.4)   55.8 (49.8-61.6)†   
             
Number of Total Providers             
1 68.7 (66.9-70.5) ref  58.6 (51.0-65.9) ref  69.1 (64.6-73.4)* ref  69.0 (67.0-70.9)* ref  
2 - 3 67.2 (64.9-69.5) 0.96 (0.92-1.00) 0.06 60.7 (52.0-68.7) 1.12 (0.92-1.36) 0.25 65.4 (59.6-70.7) 0.93 (0.84-1.04) 0.18 67.7 (65.1-70.1) 0.96 (0.91-1.00) 0.06 
4 or more 63.4 (60.2-66.5)† 0.92 (0.87-0.98) 0.01 67.7 (56.2-77.5) 1.21 (0.97-1.50) 0.10 63.7 (55.8-70.9)* 0.94 (0.84-1.07) 0.35 63.3 (59.7-66.7)*† 0.92 (0.86-0.98) 0.00 
             
Physician contacts within past year             
None  64.2 (60.4-67.9)† 0.91 (0.85-0.96) 0.00 59.2 (44.9-72.1) 1.04 (0.81-1.34) 0.74 58.2 (47.7-68.0)† 0.82 (0.69-0.96) 0.01 64.9 (60.7-68.8)† 0.90 (0.85-0.96) 0.00 
1 63.9 (61.3-66.5)† 0.84 (0.80-0.89) 0.00 60.1 (49.3-69.9) 0.96 (0.76-1.22) 0.75 61.8 (55.0-68.1)† 0.82 (0.73-0.92) 0.00 64.2 (61.4-67.0)† 0.84 (0.80-0.89) 0.00 
2 - 3 66.3 (64.1-68.5)† 0.88 (0.84-0.91) 0.00 59.5 (50.5-67.9) 0.97 (0.80-1.19) 0.80 67.8 (62.4-72.7) 0.90 (0.81-0.99) 0.03 66.4 (63.9-68.8)† 0.87 (0.83-0.91) 0.00 
4 or more 74.9 (72.8-76.8) ref  63.6 (54.2-72.1) ref  74.6 (69.0-79.5) ref  75.3 (73.0-77.4) ref  
             
Facility Type             
Private 71.1 (69.3-72.8) ref  66.1 (57.8-73.5) ref  73.2 (68.8-77.1) ref  71.0 (69.1-72.8) ref  
Public 55.2 (51.6-58.6)† 0.87 (0.81-0.92) 0.00 54.2 (43.6-64.4) 0.85 (0.67-1.07) 0.15 48.8 (40.3-57.3)† 0.74 (0.62-0.89) 0.00 55.9 (51.9-59.8)† 0.88 (0.82-0.94) 0.00 
Hospital 65.8 (61.4-70.0)† 0.96 (0.89-1.02) 0.18 51.5 (35.3-67.4) 0.83 (0.62-1.11) 0.17 75.8 (64.3-84.5)* 1.06 (0.93-1.20) 0.40 65.2 (60.4-69.8)† 0.95 (0.88-1.02) 0.13 
Mixed 67.0 (64.0-69.8)† 0.97 (0.92-1.02) 0.21 62.6 (52.6-71.7) 0.87 (0.69-1.09) 0.20 63.4 (56.2-69.9)† 0.95 (0.84-1.07) 0.41 67.5 (64.2-70.7) 0.98 (0.92-1.03) 0.39 
Other 61.3 (53.6-68.5)† 0.95 (0.85-1.06) 0.34 NA NA NA 50.9 (33.4-68.2)† 0.80 (0.59-1.10) 0.10 62.5 (54.1-70.2)† 0.96 (0.86-1.08) 0.51 
             
MSA             
Urban area 65.6 (63.6-67.6) 0.97 (0.93-1.02) 0.24 50.1 (40.4-59.8) 0.81 (0.64-1.01) 0.06 66.4 (61.3-71.1)* 1.06 (0.92-1.21) 0.40 65.9 (63.7-68.0)* 0.96 (0.91-1.01) 0.14 
Suburban area  68.9 (66.9-71.0) 0.96 (0.91-1.01) 0.09 69.4 (60.6-76.9) 1.03 (0.86-1.23) 0.76 71.0 (66.0-75.5)† 1.08 (0.95-1.23) 0.22 68.7 (66.5-70.9) 0.94 (0.89-0.99) 0.03 
Rural area 67.6 (65.0-70.1) ref  62.7 (55.0-69.8) ref  58.0 (50.1-65.5) ref  69.3 (66.4-72.1) ref  
* p-value < 0.05 compared with DRA Counties; † p-value < 0.05 compared with reference level; NA= Not Applicable  
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Table 6. Unvaccinated adolescent females aged 13-17 years by age at interview, National Immunization Survey-Teen, 
United States, 2008 - 2012 
Unvaccinated Adolescent Females  
United States 
Delta Regional Authority States 
(DRA) 
Rest of US 
DRA Counties 
Non-DRA 
Counties 
Weighted 
Proportion         % 
(95% C.I.) 
Weighted 
Proportion         % 
(95% C.I.) 
Weighted 
Proportion         % 
(95% C.I.) 
Weighted 
Proportion         % 
(95% C.I.) 
     
Does teen intend to receive HPV vaccination  
Very likely 21.4 (20.4-22.4) 23.8 (20.6-27.4) 23.2 (21.1-25.5) 21.1 (20.0-22.2) 
Somewhat likely 18.5 (17.6-19.4) 20.6 (17.4-24.2) 18.5 (16.7-20.5) 18.4 (17.4-19.4) 
Not too likely 17.6 (16.8-18.5) 17.6 (14.9-20.7) 17.5 (15.7-19.5) 17.6 (16.7-18.7) 
Not too likely at all 34.3 (33.2-35.4) 29.2 (25.8-32.9) 32.8 (30.5-35.3) 34.7 (33.5-36.0) 
Not sure/Don't know 8.2 (7.5-9.0) 8.8 (6.7-11.5) 7.9 (6.4-9.7) 8.2 (7.4-9.1) 
Reasons for not vaccinating with HPV 
Not Needed or Not Necessary 20.1 (18.9-21.4) 23.6 (19.1-28.8) 23.0 (20.2-26.1) 19.6 (18.3-21.1) 
 Safety Concern / Side Effects 14.4 (13.4-15.4) 18.2 (14.4-22.8) 13.8 (11.7-16.2) 14.3 (13.2-15.5) 
 Not Sexually Active 18.4 (17.3-19.5) 17.3 (13.7-21.7) 19.0 (16.3-22.0) 18.3 (17.1-19.6) 
 Lack of Knowledge 16.6 (15.4-17.9) 16.6 (12.7-21.3) 15.7 (13.5-18.2) 16.7 (15.3-18.2) 
 Not Recommended 11.7 (10.7-12.8) 12.1 (9.1-15.8) 11.5 (9.5-13.9) 11.7 (10.6-12.9) 
 Not Appropriate Age 6.5 (5.9-7.3) 4.5 (3.1-6.6) 7.5 (5.8-9.7) 6.5 (5.8-7.3) 
 Family / Parental Decision 3.9 (3.4-4.5) 4.1 (2.3-7.1) 5.0 (3.5-7.1) 3.8 (3.2-4.4) 
 Costs 3.1 (2.5-3.7) 3.0 (1.8-4.9) 1.7 (1.1-2.8) 3.2 (2.6-4.0) 
 More Info / New Vaccine 3.8 (3.3-4.4) 2.7 (1.5-4.7) 2.7 (1.9-3.9) 4.0 (3.4-4.6) 
 Child Should Make Decision 1.5 (1.2-2.0) 2.6 (1.3-5.3) 2.0 (1.2-3.2) 1.4 (1.0-2.0) 
 Other Reason 1.7 (1.4-2.2) 1.3 (0.5-3.2) 1.7 (1.0-2.9) 1.8 (1.4-2.2) 
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